CN111542338A - 含核酸脂质纳米粒子及其用途 - Google Patents
含核酸脂质纳米粒子及其用途 Download PDFInfo
- Publication number
- CN111542338A CN111542338A CN201880084376.1A CN201880084376A CN111542338A CN 111542338 A CN111542338 A CN 111542338A CN 201880084376 A CN201880084376 A CN 201880084376A CN 111542338 A CN111542338 A CN 111542338A
- Authority
- CN
- China
- Prior art keywords
- vivo
- cell
- cells
- lipid nanoparticle
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 170
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 129
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 50
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 109
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 109
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 108
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 100
- 210000002865 immune cell Anatomy 0.000 claims abstract description 82
- -1 cationic lipid Chemical class 0.000 claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 47
- 238000001727 in vivo Methods 0.000 claims abstract description 25
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 58
- 239000000427 antigen Substances 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000003446 ligand Substances 0.000 claims description 37
- 238000009739 binding Methods 0.000 claims description 30
- 241000124008 Mammalia Species 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 87
- 150000003839 salts Chemical class 0.000 description 38
- 239000003153 chemical reaction reagent Substances 0.000 description 32
- 229920001223 polyethylene glycol Polymers 0.000 description 32
- 239000002202 Polyethylene glycol Substances 0.000 description 31
- 125000002091 cationic group Chemical group 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 29
- 125000006239 protecting group Chemical group 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 23
- 150000003254 radicals Chemical class 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000002585 base Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000007853 buffer solution Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 210000004986 primary T-cell Anatomy 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 210000000822 natural killer cell Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000002523 gelfiltration Methods 0.000 description 7
- 150000007529 inorganic bases Chemical class 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 150000007524 organic acids Chemical class 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000001350 alkyl halides Chemical class 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical class ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 101710160107 Outer membrane protein A Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 4
- ZISVTYVLWSZJAL-UHFFFAOYSA-N 3,6-bis[4-[bis(2-hydroxydodecyl)amino]butyl]piperazine-2,5-dione Chemical compound CCCCCCCCCCC(O)CN(CC(O)CCCCCCCCCC)CCCCC1NC(=O)C(CCCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)NC1=O ZISVTYVLWSZJAL-UHFFFAOYSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical group COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- ADEORFBTPGKHRP-UHFFFAOYSA-N 1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(C)C)=CC=C2C(C)=C1N1C(=O)C=CC1=O ADEORFBTPGKHRP-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XIIAYQZJNBULGD-XWLABEFZSA-N 5α-cholestane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 XIIAYQZJNBULGD-XWLABEFZSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 2
- 206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 206010028729 Nasal cavity cancer Diseases 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 241001662443 Phemeranthus parviflorus Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000032383 Soft tissue cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 2
- 210000002255 anal canal Anatomy 0.000 description 2
- 201000007696 anal canal cancer Diseases 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000003956 middle ear cancer Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 238000005648 named reaction Methods 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000002524 peritoneal carcinoma Diseases 0.000 description 2
- 229910000064 phosphane Inorganic materials 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 201000003437 pleural cancer Diseases 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000011294 ureter cancer Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- JQMQKOQOLPGBBE-ZNCJEFCDSA-N (3s,5s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,5,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-6-one Chemical compound C([C@@H]1C(=O)C2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 JQMQKOQOLPGBBE-ZNCJEFCDSA-N 0.000 description 1
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical group C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical group O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MWESMYJLFQVSSO-UHFFFAOYSA-N 2-aminoethanethiol;4-methylbenzenesulfonic acid Chemical compound NCCS.CC1=CC=C(S(O)(=O)=O)C=C1 MWESMYJLFQVSSO-UHFFFAOYSA-N 0.000 description 1
- IKQSNVOJJISMJS-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C+](C)C IKQSNVOJJISMJS-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- WWMSFXCFODNXQS-UHFFFAOYSA-N 3-pentyloctanoic acid Chemical compound CCCCCC(CC(O)=O)CCCCC WWMSFXCFODNXQS-UHFFFAOYSA-N 0.000 description 1
- NZBKIOJQXNGENQ-UHFFFAOYSA-N 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium Chemical compound COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 NZBKIOJQXNGENQ-UHFFFAOYSA-N 0.000 description 1
- JQMQKOQOLPGBBE-UHFFFAOYSA-N 6-ketocholestanol Natural products C1C(=O)C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 JQMQKOQOLPGBBE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 102100034681 Myeloblastin Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000000581 Triticum monococcum Species 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 102000040856 WT1 Human genes 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 101150084041 WT1 gene Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 238000006734 Wohl-Ziegler bromination reaction Methods 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- LJGMGXXCKVFFIS-IATSNXCDSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] decanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCC)C1 LJGMGXXCKVFFIS-IATSNXCDSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940107816 ammonium iodide Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000002841 anti-cancer assay Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GLGAUBPACOBAMV-DOFZRALJSA-N arachidonylcyclopropylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1CC1 GLGAUBPACOBAMV-DOFZRALJSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 150000004792 aryl magnesium halides Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000005311 autocorrelation function Methods 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- AWNLOVXXKLDDSM-UHFFFAOYSA-N benzo[a]anthracen-1-yl(silyl)silane Chemical compound C1(=CC=CC2=CC=C3C=C4C=CC=CC4=CC3=C12)[SiH2][SiH3] AWNLOVXXKLDDSM-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical class C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical group NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- LUFPJJNWMYZRQE-UHFFFAOYSA-N benzylsulfanylmethylbenzene Chemical group C=1C=CC=CC=1CSCC1=CC=CC=C1 LUFPJJNWMYZRQE-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001869 cobalt compounds Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000002897 diene group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical group C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000013335 mesoporous material Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical group CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical group COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 150000002816 nickel compounds Chemical class 0.000 description 1
- KFBKRCXOTTUAFS-UHFFFAOYSA-N nickel;triphenylphosphane Chemical compound [Ni].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 KFBKRCXOTTUAFS-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 150000002941 palladium compounds Chemical class 0.000 description 1
- ULYNIEUXPCUIEL-UHFFFAOYSA-L palladium(2+);triethylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CCP(CC)CC.CCP(CC)CC ULYNIEUXPCUIEL-UHFFFAOYSA-L 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical class OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000007154 radical cyclization reaction Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003284 rhodium compounds Chemical class 0.000 description 1
- FCQRKDSALKMOGU-UHFFFAOYSA-K rhodium(3+);triphenylphosphane;trichloride Chemical compound Cl[Rh](Cl)Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FCQRKDSALKMOGU-UHFFFAOYSA-K 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical group CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical group CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical group C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- KBLZDCFTQSIIOH-UHFFFAOYSA-M tetrabutylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC KBLZDCFTQSIIOH-UHFFFAOYSA-M 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N tetradec-9-enoic acid Chemical compound CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical group CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 238000005936 thiocarbonylation reaction Methods 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- XQKBFQXWZCFNFF-UHFFFAOYSA-K triiodosamarium Chemical compound I[Sm](I)I XQKBFQXWZCFNFF-UHFFFAOYSA-K 0.000 description 1
- HUYHHHVTBNJNFM-UHFFFAOYSA-N trimethylsilylsilicon Chemical compound C[Si](C)(C)[Si] HUYHHHVTBNJNFM-UHFFFAOYSA-N 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical group C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- SJHCUXCOGGKFAI-UHFFFAOYSA-N tripropan-2-yl phosphite Chemical compound CC(C)OP(OC(C)C)OC(C)C SJHCUXCOGGKFAI-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- XIIAYQZJNBULGD-CJPSHIORSA-N β-cholestane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 XIIAYQZJNBULGD-CJPSHIORSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
Abstract
本发明提供了一种脂质纳米粒子,其含有以下组分(a)至(c):(a)编码嵌合抗原受体(CAR)或外源性T细胞受体(TCR)的核酸;(b)阳离子脂质;和(c)非阳离子脂质。本发明还提供了一种表达CAR或表达外源性TCR的免疫细胞,其通过将所述脂质纳米粒子引入体内或离体T细胞而产生;以及一种使用所述免疫细胞治疗包括癌症的疾病的体内或离体治疗手段。
Description
技术领域
本发明涉及含有编码嵌合抗原受体或T细胞受体的核酸的脂质纳米粒子;通过使用所述脂质纳米粒子在感兴趣的免疫细胞中表达嵌合抗原受体或外源性T细胞受体的方法;其药物用途;等。
背景技术
使用引入了源自癌症抗原特异性杀伤T细胞的嵌合抗原受体(CAR)或T细胞受体(TCR)的基因的CAR-T细胞或TCR-T细胞进行癌症免疫疗法的研究和发展进展迅速。当前的CAR-T细胞疗法,诸如在美国获得批准的Kymriah(商品名)和Yescarta(商品名),通常包括通过使用病毒载体诸如慢病毒载体转染从具有CAR基因的患者收集的离体T细胞来制备CAR-T细胞,并向患者施用CAR-T细胞。然而,该方法的问题在于,由于细胞培养和病毒载体制备的成本,生产成本变高。如果可以将CAR或外源性TCR选择性地引入体内免疫细胞例如T细胞,那么无需离体制备,并且可以提供生产成本低的CAR-或TCR-免疫细胞疗法。另外,如果可以在不使用需要高生产成本的病毒载体的情况下将CAR或外源性TCR选择性地离体引入免疫细胞例如T细胞,那么消除了病毒残留检测等的成本,并且可以提供生产成本低的CAR-或TCR-免疫细胞疗法。
已经报道了CAR向T细胞的离体或体内转染,其使用含有编码CAR的质粒DNA和阳离子聚合物的聚集体的纳米粒子,所述聚集体被与抗CD3抗体片段缀合的非阳离子聚合物包被(专利文献1,非专利文献1);或者使用含有介孔二氧化硅的纳米载体,所述介孔二氧化硅在孔中包封了编码CAR的DNA并包被有具有被抗CD3抗体修饰的表面的脂质(专利文献2)。
除此之外,已经报道了通过将靶siRNA包封在“脂质纳米粒子(LNP)”中将siRNA递送至靶细胞的技术,所述“脂质纳米粒子(LNP)”没有内部孔结构并且由阳离子脂质、非阳离子辅助脂质以及用于递送至靶细胞的配体组成。例如,已经报道了通过使用抗CD4抗体片段作为靶向配体将用于CD45的siRNA离体或体内转染到T细胞中(专利文献3,非专利文献2)。
然而,迄今为止,没有报道通过使用LNP将编码CAR或外源性TCR的核酸(例如,mRNA,DNA)选择性地引入免疫细胞例如T细胞中。
现有技术文献
专利文献
专利文献1:US 2017/0296676
专利文献2:US 2016/0145348
专利文献3:WO 2016/189532
非专利文献
非专利文献1:Nature Nanotechnology 12,813-820(2017)
非专利文献2:ACS Nano,2015,9(7),6706-6716
发明内容
技术问题
本发明的目的是提供一种新颖的转染技术,其能够有效地将CAR或外源性TCR选择性地引入体内或离体的免疫细胞诸如T细胞,从而以低生产成本提供CAR-或TCR-免疫细胞疗法。本发明的另一个目的是提供一种避免病毒蛋白抗原性问题的更安全的CAR-或TCR-免疫细胞疗法。
问题的解决方案
为了实现上述目的,本发明人进行了深入研究,并成功地通过使用LNP有效地将编码CAR或外源性TCR的核酸选择性地引入体内或离体的免疫细胞诸如T细胞中,从而完成了本发明。
因此,本发明提供以下内容。
[1]一种脂质纳米粒子,其包含以下(a)至(c):
(a)编码嵌合抗原受体或外源性T细胞受体的核酸;
(b)阳离子脂质;和
(c)非阳离子脂质。
[2][1]的脂质纳米粒子,其中前述阳离子脂质为式(I)表示的化合物或其盐:
其中
L1为C1-22亚烷基、C2-22亚烯基或C3-22亚二烯基,
n为0或1的整数,
R1为
(1)氢原子,
(2)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(3)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(4)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
R2为-CH2-O-CO-R5、-CH2-CO-O-R5或-R5,
R3为-CH2-O-CO-R6、-CH2-CO-O-R6或-R6,
R4为氢原子、-CH2-O-CO-R7、-CH2-CO-O-R7或-R7,
R5、R6和R7各自独立地为
(1)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(2)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(3)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
R8和R9各自独立地为C1-6烷基。
[3][1]或[2]的脂质纳米粒子,其中前述核酸为mRNA或DNA。
[4][1]至[3]中任一项的脂质纳米粒子,其中前述非阳离子脂质为磷脂、胆固醇和/或PEG脂质。
[5][1]至[4]中任一项的脂质纳米粒子,其中前述脂质纳米粒子在表面上具有可以靶向T细胞的配体。
[6][5]的脂质纳米粒子,其中前述配体是包含选自以下的一种或多种抗体的抗原结合结构域的配体:抗CD3的抗体、抗CD4的抗体、抗CD8的抗体和抗CD28的抗体。
[7][5]的脂质纳米粒子,其中前述配体是包含抗CD3的抗体和/或抗CD28的抗体的抗原结合结构域的配体。
[8][5]的脂质纳米粒子,其中前述配体是包含抗CD3的抗体和抗CD28的抗体的抗原结合结构域的配体。
[9]一种药物,其包含[1]至[8]中任一项的脂质纳米粒子。
[10][9]的药物,其中所述药物是用于癌症的预防或治疗药物。
[11][9]的药物,其中所述药物将嵌合抗原受体或外源性T细胞受体基因引入体内免疫细胞以诱导其表达。
[12][9]的药物,其中所述药物将嵌合抗原受体或外源性T细胞受体基因引入体内T细胞以诱导其表达。
[13]一种通过将嵌合抗原受体或外源性T细胞受体引入哺乳动物的体内免疫细胞来表达所述受体的方法,所述方法包含向所述哺乳动物施用[1]至[8]中任一项的脂质纳米粒子。
[14]一种通过将嵌合抗原受体或外源性T细胞受体引入哺乳动物的体内T细胞来表达所述受体的方法,所述方法包含向所述哺乳动物施用[1]至[8]中任一项的脂质纳米粒子。
[15]一种用于预防或治疗哺乳动物中的癌症的方法,所述方法包含向所述哺乳动物施用[1]至[8]中任一项的脂质纳米粒子。
[16][1]至[8]中任一项的脂质纳米粒子,其用于预防或治疗癌症。
[17][1]至[8]中任一项的脂质纳米粒子在制造用于预防或治疗癌症的药剂中的用途。
[18]一种用于诱导嵌合抗原受体或外源性T细胞受体表达的组合物,其包含[1]至[8]中任一项的脂质纳米粒子。
[19]一种离体免疫细胞,其表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
[20]一种离体T细胞,其表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
[21]一种包含离体免疫细胞的药物,所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
[22]一种包含离体T细胞的药物,所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
[23][21]或[22]的药物,其中所述药物是用于癌症的预防或治疗药物。
[24][21]或[22]的药物,其中所述药物是用于诱导细胞凋亡的药物。
[25]一种通过将嵌合抗原受体或外源性T细胞受体引入离体免疫细胞来表达所述受体的方法,所述方法包含将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中。
[26]一种用于在离体T细胞中表达嵌合抗原受体或外源性T细胞受体的方法,所述方法包含将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中。
[27]一种用于预防或治疗哺乳动物中的癌症的方法,所述方法包含向所述哺乳动物施用离体免疫细胞,所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
[28]一种用于预防或治疗哺乳动物中的癌症的方法,所述方法包含向所述哺乳动物施用离体T细胞,所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
[29]一种用于预防或治疗癌症的离体免疫细胞,其中所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
[30]一种用于预防或治疗癌症的离体T细胞,其中所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
[31]离体免疫细胞在制造用于预防或治疗癌症的药剂中的用途,其中所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
[32]离体T细胞在制造用于预防或治疗癌症的药剂中的用途,其中所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
[33]一种制备药物的方法,所述药物包含表达嵌合抗原受体或外源性T细胞受体的离体免疫细胞,所述方法包含以下步骤:将[1]至[8]中任一项的脂质纳米粒子添加到包含离体免疫细胞的培养物中。
[34]一种制备药物的方法,所述药物包含表达嵌合抗原受体或外源性T细胞受体的离体T细胞,所述方法包含以下步骤:将[1]至[8]中任一项的脂质纳米粒子添加到包含离体T细胞的培养物中。
发明的有利效果
根据本发明,CAR或外源性TCR不仅可以离体而且可以在体内有效地选择性地引入免疫细胞诸如T细胞中,并且可以提供生产成本低的CAR-或TCR-免疫细胞疗法。另外,由于不使用病毒载体,因此可以避免病毒蛋白的抗原性问题。
附图说明
图1显示了在用hCD3/hCD28-化合物12-pcDNA3.1-hCD19CAR转染的培养的人原代T细胞中CD19 CAR表达的流式细胞术分析结果。
图2显示了在用hCD3/hCD28-化合物21-pcDNA3.1-hCD19CAR和hCD3/hCD28-化合物35-pcDNA3.1-hCD19CAR转染的培养的人原代T细胞中CD19 CAR表达的流式细胞术分析结果。
图3显示了通过添加用CD19 CAR转染的培养的人原代T细胞,Nalm-6和Daudi的细胞毒性率。
具体实施方式
1.本发明的脂质纳米粒子(LNP)
本发明提供了含有以下(a)至(c)的脂质纳米粒子:
(a)编码嵌合抗原受体(CAR)或外源性T细胞受体(TCR)的核酸;
(b)阳离子脂质;和
(c)非阳离子脂质
(在下文中也称为“本发明的脂质纳米粒子”,“本发明的LNP”)。
在本说明书中,“脂质纳米粒子(LNP)”是指由上述(b)和(c)构成的分子集合体中的平均直径小于1μm且没有小的多孔结构(例如,介孔材料)的粒子。
以下对本发明的脂质纳米粒子的构成要素(a)至(c)进行解释。
(a)编码嵌合抗原受体(CAR)或外源性T细胞受体(TCR)的核酸
(a-1)编码CAR的核酸
CAR是人工构建的杂合蛋白,其含有与T细胞信号转导结构域偶联的抗体的抗原结合结构域(例如,scFv)。CAR的特征在于能够利用单克隆抗体的抗原结合特性以非MHC限制的方式将T细胞的特异性和响应性重定向至选定的靶标。非MHC限制的抗原识别向表达CAR的T细胞赋予了独立于抗原加工而识别抗原的能力,从而绕开了肿瘤逃逸的主要机制。此外,当在T细胞中表达时,CAR有利地不与内源性TCR α链和β链二聚化。
用于本发明的脂质纳米粒子的CAR包括可以特异性识别靶免疫细胞(例如T细胞、NK细胞、NKT细胞、单核细胞、巨噬细胞、树突状细胞等)应识别的表面抗原(例如,癌症抗原肽、在癌细胞中显示出促进表达的表面受体等)的抗体的抗原结合结构域、细胞外铰链结构域、跨膜结构域和细胞内T细胞信号转导结构域。
被抗原结合结构域特异性识别的表面抗原的实例包括但不限于在各种癌症中显示出促进表达的表面受体,所述癌症例如急性淋巴细胞癌、肺泡横纹肌肉瘤、膀胱癌、骨癌、脑癌(例如髓母细胞瘤)、乳腺癌、肛门、肛管或肛门直肠癌、眼癌、肝内胆管癌、关节癌、子宫颈癌、胆囊癌或胸膜癌、鼻癌、鼻腔癌或中耳癌、口腔癌、外阴癌、慢性髓细胞癌、结肠癌、食道癌、子宫颈癌、纤维肉瘤、胃肠类癌、头颈癌(例如头颈鳞状细胞癌)、下咽癌、肾癌、喉癌、白血病(例如急性淋巴母细胞白血病、急性淋巴细胞白血病、慢性淋巴细胞白血病、急性髓细胞白血病)、液体肿瘤、肝癌、肺癌(例如非小细胞肺癌)、淋巴瘤(例如霍奇金淋巴瘤、非霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤)、恶性间皮瘤、肥大细胞瘤、黑素瘤、多发性骨髓瘤、鼻咽癌、卵巢癌、胰腺癌、腹膜癌、大网膜癌和肠系膜癌;咽癌、前列腺癌、直肠癌、肾癌、皮肤癌、小肠癌、软组织癌、实体肿瘤、胃癌、睾丸癌、甲状腺癌、输尿管癌等,所述表面受体例如CD19、EGF受体、BCMA、CD30、Her2、ROR1、MUC16、CD20、间皮素、B细胞突变抗原(BCMA)、CD123、CD3、前列腺特异性膜抗原(PSMA)、CD33、MUC-1、CD138、CD22、GD2、PD-L1、CEA、硫酸软骨素蛋白聚糖-4、IL-13受体α链、IgG κ轻链和癌症抗原肽(例如源自WT1、GPC3、MART-1、gp100、NY-ESO-1、MAGE-A4等的肽)。
对本发明中使用的抗原结合结构域没有特别限制,只要它是可以特异性识别靶抗原的抗体片段即可。考虑到CAR的制备容易性,期望的是其中轻链可变区和重链可变区通过连接肽连接的单链抗体(scFv)。单链抗体中的轻链可变区和重链可变区的构型没有特别限制,只要它们可以重构功能性抗原结合结构域即可。从N末端侧开始,通常可以按照轻链可变区、连接肽和重链可变区的顺序设计它们。作为连接肽,可以使用通常用于制备单链抗体的已知的连接肽。例如,编码轻链可变区和重链可变区的DNA可以通过分别从产生抗体的细胞中克隆轻链基因和重链基因并使用它们作为模板进行PCR等,或者通过从现有抗体的序列信息化学合成它们来制备。通过以适当的方法将每个获得的DNA片段与编码连接肽的DNA连接,可以获得编码单链抗体的DNA。优选在抗原结合结构域的N-末端侧进一步添加阅读器序列以将CAR呈递至免疫细胞的表面。
作为细胞外铰链结构域和跨膜结构域,可以适当地使用在相关技术领域中通常使用的源自T细胞表面分子的结构域。例如,它们包括但不限于源自于CD8α和CD28的结构域。
细胞内信号转导结构域的实例包括但不限于具有CD3ζ链的那些,在跨膜结构域与CD3ζ链之间进一步具有共刺激基序例如CD28、CD134、CD137、Lck、DAP10、ICOS、4-1BB等的那些,以及具有两个或更多个共刺激基序的那些。在相关技术领域中通常使用的任何结构域都可以组合使用。
编码细胞外铰链结构域、跨膜结构域和细胞内信号转导结构域的核酸序列信息在相关技术领域中是众所周知的。基于这种信息,本领域普通技术人员可以容易地从T细胞获得编码每个结构域的DNA片段。
通过用常规方法将分别编码如此获得的抗原结合结构域、细胞外铰链结构域、跨膜结构域和细胞内信号转导结构域的DNA片段连接,可以获得编码CAR的DNA。
可以将获得的编码CAR的DNA按原样或在添加合适的连接子和/或核易位信号等之后插入到含有T细胞内的功能性启动子的表达载体,优选质粒载体中。T细胞内的功能性启动子的实例包括但不限于哺乳动物细胞中的组成型SRα启动子、SV40启动子、LTR启动子、CMV(巨细胞病毒)启动子、RSV(鲁氏肉瘤病毒)启动子、MoMuLV(莫洛尼小鼠白血病病毒)LTR、HSV-TK(单纯疱疹病毒胸苷激酶)启动子等。另外,还可以使用在T细胞中特异性表达的基因启动子,诸如CD3、CD4和CD8。
可以使用含有编码上述CAR的DNA的表达载体作为模板,通过在本身已知的体外转录系统中转录成mRNA来制备编码CAR的RNA,优选mRNA。
(a-2)编码外源性TCR的核酸
在本说明书中,“T细胞受体(TCR)”是指由TCR链(α链,β链)的二聚体组成并识别抗原或抗原-HLA(人类白细胞型抗原)(MHC;主要组织相容性复合物)复合物并向T细胞转导刺激信号的受体。每条TCR链都由可变区和恒定区组成,并且可变区含有三个互补决定区(CDR1,CDR2,CDR3)。用于本发明的TCR不仅包括其中TCR的α和β链构成异二聚体的那些,而且还包括其中它们构成同二聚体的那些。此外,TCR包括缺失了部分或全部恒定区的那些、具有重组的氨基酸序列的那些以及具有可溶性TCR的那些,等等。
“外源性TCR”是指对本发明的脂质纳米粒子的靶细胞即T细胞而言是外源的。外源性TCR的氨基酸序列可以与作为本发明脂质纳米粒子的靶细胞的T细胞表达的内源性TCR的氨基酸序列相同或不同。
在本发明的脂质纳米粒子中使用的编码TCR的核酸是编码TCR的α链和β链的核酸,所述TCR可以特异性地识别将被靶T细胞识别的表面抗原(例如,癌症抗原肽等)。
可以通过本身已知的方法制备核酸。当所需TCR的氨基酸序列或核酸序列已知时,可以基于所述序列,例如通过利用PCR方法或吉布森组装法化学合成DNA链或RNA链或连接合成的部分重叠的寡DNA短链,来构建编码本发明的TCR的全长或一部分的DNA。
当所需TCR的序列未知时,例如,从含有表达感兴趣的TCR的T细胞的细胞群中分离感兴趣的T细胞,并且可以从T细胞获得编码TCR的核酸。具体地,从生物体(例如人)收集含有T细胞的细胞群(例如PBMC),在刺激细胞群的同时在靶TCR识别的细胞表面抗原的表位的存在下培养细胞群,并且可以通过已知方法并使用对表达细胞表面抗原的细胞和细胞表面抗原例如CD8和CD4的特异性作为指标,从细胞群中选择特异性识别表达细胞表面抗原的细胞的T细胞。对于表达T细胞的细胞表面抗原的细胞的特异性可以例如通过右旋体测定、ELISPOT测定、细胞毒性测定等来测量。前述含有T细胞的细胞群优选地从例如具有大量表达被感兴趣的TCR识别的细胞表面抗原的细胞的生物体中收集(例如,患有疾病例如癌症的患者,或与抗原表位或被表位脉冲化的树突状细胞接触的含T细胞的群体)。
本发明的核酸可通过以下方法获得:通过常规方法从上述分离的T细胞中提取DNA,并以该DNA为模板,基于TCR恒定区的核酸序列扩增和克隆TCR基因。它也可以通过以下方法制备:通过常规方法从细胞中提取RNA并合成cDNA,并使用与分别编码TCR α链和β链的恒定区的核酸互补的反义引物,以cDNA为模板进行5′-RACE(cDNA末端的快速扩增)。5’-RACE可以通过已知的方法进行,例如可以使用可商购的试剂盒例如SMART PCR cDNA合成试剂盒(clontech公司制)进行。可以以与编码上述CAR的DNA相同的方式,将编码获得的TCR的α链和β链的DNA插入适当的表达载体中。可以将编码α链的DNA和编码β链的DNA插入相同的载体或单独的载体中。当插入相同载体中时,表达载体可以多顺反子或单顺反子方式表达两条链。在前一种情况下,将允许多顺反子表达的插入序列例如IRES或FMV2A插入编码两条链的DNA之间。
另外,例如,可以使用表达载体作为模板,以与上述编码CAR的RNA相同的方式制备编码TCR的每条链的RNA,优选mRNA。
(b)阳离子脂质
在本说明书中,“阳离子脂质”是指在选定的pH诸如生理pH下具有净正电荷的脂质。对本发明的脂质纳米粒子中使用的阳离子脂质没有特别限制。例如,可以提及WO 2015/011633、WO 2016/021683、WO 2011/153493、WO 2013/126803、WO 2010/054401、WO 2010/042877、WO 2016/104580、WO 2015/005253、WO 2014/007398、WO 2017/117528、WO 2017/075531、WO 2017/00414、WO 2015/199952、US 2015/0239834等中描述的阳离子脂质等。
优选的阳离子脂质由以下结构式表示并描述于WO 2015/011633中。
及其盐。
在上述阳离子脂质中,更优选由以下结构式表示的阳离子脂质。
及其盐。
优选的阳离子脂质由以下结构式表示并描述于WO 2016/021683中。由下式表示的化合物:
其中
W为式-NR1R2或式-N+R3R4R5(Z-),
R1和R2各自独立地为C1-4烷基或氢原子,
R3、R4和R5各自独立地为C1-4烷基,
Z-为阴离子,
X为任选取代的C1-6亚烷基,
YA、YB和YC各自独立地为任选取代的次甲基,
LA、LB和LC各自独立地为任选取代的亚甲基或键,并且
RA1、RA2、RB1、RB2、RC1和RC2各自独立地为任选取代的C4-10烷基,
或其盐。
更优选地,可以提及由以下结构式表示的阳离子脂质。
及其盐。
在上述阳离子脂质中,更优选的阳离子脂质由以下结构式表示。
及其盐。
在另一个优选实施方案中,可以提及由下式(II)表示的阳离子脂质(在下文中也称为“化合物(II)”)。由下式表示的化合物:
其中
n为2至5的整数,
R为直链C1-5烷基、直链C7-11烯基或直链C11二烯基,并且波浪线各自独立地显示顺式或反式键,
或其盐。
更优选地,可以提及由以下结构式表示的阳离子脂质。
及其盐。
在上述阳离子脂质中,更优选的阳离子脂质由以下结构式表示。
及其盐。
化合物(II)可以例如通过以下制备方法制备。在化合物(II)中,两个波浪线均为顺式键的化合物和一个或两个波浪线为反式键的化合物都可以通过与以下所示的制备方法类似的方法来制备。特别地,根据所需化合物(II)的结构,可以在酯化过程中使用适当的起始物质合成具有所需结构的化合物(II)。化合物(II)的盐可以通过与无机碱、有机碱、有机酸、碱性或酸性氨基酸适当混合而获得。
在上述制备方法的每个步骤中使用的起始物质或试剂以及所获得的化合物可以各自形成盐。
当在每个步骤中获得的化合物是游离化合物时,可以通过本领域本身已知的方法将该化合物转化为感兴趣的盐。相反,当在每个步骤中获得的化合物是盐时,可以通过本领域本身已知的方法将该盐转化为游离形式或另一类感兴趣的盐。
在每个步骤中获得的化合物可以以其反应溶液的形式直接用于下一反应或在以粗产物形式获得后用于下一反应。或者,可以根据常规方法,通过分离方法,诸如浓缩、结晶、重结晶、蒸馏、溶剂萃取、分馏或色谱法,从反应混合物中分离和/或纯化在每个步骤中获得的化合物。
如果用于每个步骤的起始物质或试剂化合物是可商购的,那么可以直接使用可商购的产品。
在每个步骤的反应中,反应时间可以根据所使用的试剂或溶剂而不同,除非另有说明,否则通常为1分钟至48小时,优选10分钟至8小时。
在每个步骤的反应中,反应温度可以根据所使用的试剂或溶剂而不同,除非另有说明,否则通常为-78℃至300℃,优选-78℃至150℃。
在每个步骤的反应中,压力可以根据所使用的试剂或溶剂而不同,除非另有说明,否则通常为1atm至20atm,优选1atm至3atm。
在每个步骤的反应中,例如,可以使用微波合成装置诸如BiotageInitiator。反应温度可以根据所使用的试剂或溶剂而不同,除非另有说明,否则通常为室温至300℃,优选室温至250℃,更优选50℃至250℃。反应时间可以根据所使用的试剂或溶剂而不同,除非另有说明,否则通常为1分钟至48小时,优选1分钟至8小时。
在每个步骤的反应中,除非另有说明,否则试剂相对于底物的使用量为0.5当量至20当量,优选0.8当量至5当量。在使用试剂作为催化剂的情况下,试剂相对于底物的使用量为0.001当量至1当量,优选0.01当量至0.2当量。当试剂还用作反应溶剂时,以溶剂的量使用试剂。
在反应的每个步骤中,除非另有说明,否则反应在没有溶剂的情况下进行或通过溶解或悬浮在适当的溶剂中进行。溶剂的具体实例包括以下。
醇:甲醇、乙醇、异丙醇、异丁醇、叔丁醇、2-甲氧基乙醇等;
醚:乙醚、二异丙醚、二苯醚、四氢呋喃、1,2-二甲氧基乙烷等;
芳烃:氯苯、甲苯、二甲苯等;
饱和烃:环己烷、己烷、庚烷等;
酰胺:N,N-二甲基甲酰胺、N-甲基吡咯烷酮等;
卤代烃:二氯甲烷、四氯化碳等;
腈:乙腈等;
亚砜:二甲基亚砜等;
芳族有机碱:吡啶等;
酸酐:乙酸酐等;
有机酸:甲酸、乙酸、三氟乙酸等;
无机酸:盐酸、硫酸等;
酯:乙酸乙酯、乙酸异丙酯等;
酮:丙酮、甲乙酮等;
水。
这些溶剂中的两种或更多种可以以适当的比例混合使用。
在使用碱的每个反应步骤中,可以使用的碱的实例是下面列出的那些。
无机碱:氢氧化钠、氢氧化钾、氢氧化镁等;
碱性盐:碳酸钠、碳酸钙、碳酸氢钠等;
有机碱:三乙胺、二乙胺、吡啶、4-二甲基氨基吡啶、N,N-二甲基苯胺、1,4-二氮杂双环[2.2.2]辛烷、1,8-二氮杂双环[5.4.0]-7-十一碳烯、咪唑、哌啶等;
金属醇盐:乙醇钠、叔丁醇钾、叔丁醇钠等;
碱金属氢化物:氢化钠等;
金属酰胺:氨基钠、二异丙基氨基锂、六甲基二硅基叠氮化锂等;
有机锂:正丁基锂、仲丁基锂等。
在使用酸或酸催化剂的每个反应步骤中,使用以下酸或酸催化剂。
无机酸:盐酸、硫酸、硝酸、氢溴酸、磷酸等;
有机酸:乙酸、三氟乙酸、柠檬酸、对甲苯磺酸、10-樟脑磺酸等;
路易斯酸:三氟化硼二乙醚络合物、碘化锌、无水氯化铝、无水氯化锌、无水氯化铁等。
除非另有说明,否则每个反应步骤都可以根据本领域本身已知的标准方法进行,诸如实验化学百科全书(Encyclopedia of Experimental Chemistry),第5版,第13卷至第19卷(日本化学会编);新实验化学百科全书(New Encyclopedia of ExperimentalChemistry),第14卷至第15卷(日本化学会编);精密有机化学(Fine Organic Chemistry),第2版修订版(L.F.Tietze,Th.Eicher,Nankodo);有机人名反应(Organic NameReactions);反应机理与实质(The Reaction Mechanism and Essence),修订版(HideoTogo,Kodansha);有机合成合订本I-VII(Organic Syntheses Collective Volume I-VII)(John Wiley&Sons,Inc.);实验室的现代有机合成:标准实验程序的合集(Modern OrganicSynthesis in the Laboratory:A Collection of Standard Experimental Procedures)(Jie Jack Li,Oxford University Press);综合杂环化学III(ComprehensiveHeterocyclic Chemistry III),第1卷至第14卷(Elsevier Japan KK);人名反应在有机合成中的战略应用(Strategic Applications of Named Reactions in OrganicSynthesis)(Kiyoshi Tomioka 译,Kagaku-Dojin Publishing);综合有机转化(Comprehensive Organic Transformations)(VCH Publishers,Inc.),1989等中描述的那些。
在每个步骤中,可以根据本领域本身已知的方法,例如“有机合成中的保护基(Protective Groups in Organic Synthesis),第4版”(Theodora W.Greene,PeterG.M.Wuts),Wiley-Interscience,2007;“保护基(Protecting Groups),第3版”(P.J.Kocienski)Thieme,2004)等中描述的方法,进行官能团的保护或脱保护反应。
醇等中的羟基或酚羟基的保护基的实例包括:醚型保护基,诸如甲氧基甲基醚、苄基醚、对甲氧基苄基醚、叔丁基二甲基甲硅烷基醚、叔丁基二苯基甲硅烷基醚和四氢吡喃基醚;羧酸酯型保护基,诸如乙酸酯;磺酸酯型保护基,诸如甲磺酸酯;和碳酸酯型保护基,诸如碳酸叔丁酯。
羧基的保护基的实例包括:酯型保护基,诸如甲酯;和酰胺型保护基,诸如N,N-二甲基酰胺。
硫醇的保护基的实例包括:醚型保护基,诸如苄基硫醚;和酯型保护基,诸如硫代乙酸酯、硫代碳酸酯和硫代氨基甲酸酯。
氨基或芳族杂环诸如咪唑、吡咯或吲哚的保护基的实例包括:氨基甲酸酯型保护基,诸如氨基甲酸苄酯;和酰胺型保护基,诸如乙酰胺;烷基胺型保护基,诸如N-三苯基甲胺;和磺酰胺型保护基,诸如甲磺酰胺。
可以通过使用本领域本身已知的方法,例如使用酸、碱、紫外线、肼、苯肼、N-甲基二硫代氨基甲酸钠、氟化四丁基铵、乙酸钯或三烷基甲硅烷基卤(例如,三甲基甲硅烷基碘或三甲基甲硅烷基溴)的方法或还原方法,去除保护基。
在利用还原反应的每个步骤中,可以使用的还原剂的实例包括:金属氢化物,诸如氢化铝锂、三乙酰氧基硼氢化钠、氰基硼氢化钠、二异丁基氢化铝(DIBAL-H)、硼氢化钠和四甲基三乙酰氧基硼氢化铵;硼烷,诸如硼烷-四氢呋喃络合物;雷尼镍;雷尼钴;氢;和甲酸。例如,可以在氢或甲酸的存在下使用雷尼镍或雷尼钴。在还原碳-碳双键或三键的情况下,可以使用利用催化剂诸如钯-碳或林德拉催化剂的方法。
在利用氧化反应的每个步骤中,可以使用的氧化剂的实例包括:过酸,诸如间氯过苯甲酸(MCPBA)、过氧化氢和叔丁基过氧化氢;过氯酸盐,诸如过氯酸四丁铵;氯酸盐,诸如氯酸钠;亚氯酸盐,诸如亚氯酸钠;过碘酸盐,诸如过碘酸钠;高价碘试剂,诸如亚碘酰苯;锰试剂,诸如二氧化锰和高锰酸钾;铅试剂,诸如四乙酸铅;铬试剂,诸如氯铬酸吡啶鎓(PCC)、重铬酸吡啶鎓(PDC)和琼斯试剂;卤素化合物,诸如N-溴代琥珀酰亚胺(NBS);氧;臭氧;三氧化硫-吡啶络合物;四氧化锇;二氧化硒;和2,3-二氯-5,6-二氰基-1,4-苯醌(DDQ)。
在利用自由基环化反应的每个步骤中,可以使用的自由基引发剂的实例包括:偶氮化合物,诸如偶氮二异丁腈(AIBN);水溶性自由基引发剂,诸如4-4′-偶氮双-4-氰基戊酸(ACPA);在空气或氧气存在下的三乙基硼;和过氧化苯甲酰。所使用的自由基引发剂的实例包括三丁基锡烷、三三甲基甲硅烷基硅烷、1,1,2,2-四苯基二硅烷、二苯基硅烷和碘化钐。
在利用维蒂希反应的每个步骤中,可以使用的维蒂希试剂的实例包括亚烷基膦烷。可以通过本领域本身已知的方法,例如,磷鎓盐与强碱之间的反应来制备亚烷基膦烷。
在利用霍纳-埃蒙斯反应的每个步骤中,可以使用的试剂的实例包括膦酰基乙酸酯,诸如二甲基膦酰基乙酸甲酯和二乙基膦酰基乙酸乙酯,以及碱,诸如碱金属氢化物和有机锂。
在利用弗瑞德-克来福特反应的每个步骤中,可以使用的试剂的实例包括路易斯酸和酰氯或烷基化剂(例如烷基卤化物、醇和烯烃)。或者,可以使用有机或无机酸代替路易斯酸,并且可以使用酸酐诸如乙酸酐代替酰氯。
在利用芳族亲核取代反应的每个步骤中,亲核试剂(例如,胺或咪唑)和碱(例如,碱性盐或有机碱)可以用作试剂。
在使用利用碳负离子的亲核加成反应、利用碳负离子的亲核1,4-加成反应(迈克尔加成反应)或利用碳负离子的亲核取代反应的每个步骤中,可以用于产生碳负离子的碱的实例包括有机锂试剂、金属醇盐、无机碱和有机碱。
在利用格氏反应的每个步骤中,可以使用的格氏试剂的实例包括芳基卤化镁,诸如苯基溴化镁;和烷基卤化镁,诸如甲基溴化镁、异丙基溴化镁。格氏试剂可以通过本领域本身已知的方法,例如烷基卤化物或芳基卤化物与金属镁在作为溶剂的醚或四氢呋喃中的反应,来制备。
在利用Knoevenagel缩合反应的每个步骤中,侧接有两个吸电子基团的活性亚甲基化合物(例如丙二酸、丙二酸二乙酯或丙二腈)和碱(例如有机碱、金属醇盐或无机碱)可以用作试剂。
在利用Vilsmeier-Haack反应的每个步骤中,磷酰氯和酰胺衍生物(例如N,N-二甲基甲酰胺)可以用作试剂。
在利用醇、烷基卤化物或磺酸酯的叠氮化反应的每个步骤中,可以使用的叠氮化剂的实例包括二苯基磷酰叠氮化物(DPPA)、三甲基甲硅烷基叠氮化物和叠氮化钠。在例如醇的叠氮化的情况下,可以使用利用二苯基磷酰叠氮化物和1,8-二氮杂双环[5,4,0]十一碳-7-烯(DBU)的方法、利用三甲基甲硅烷基叠氮化物和路易斯酸的方法等。
在利用还原性胺化反应的每个步骤中,可以使用的还原剂的实例包括三乙酰氧基硼氢化钠、氰基硼氢化钠、氢和甲酸。当底物是胺化合物时,可以使用的羰基化合物的实例包括对甲醛以及诸如乙醛的醛和诸如环己酮的酮。当底物是羰基化合物时,可以使用的胺的实例包括伯胺,诸如氨和甲胺,以及仲胺,诸如二甲胺。
在利用Mitsunobu反应的每个步骤中,偶氮二羧酸酯(例如偶氮二羧酸二乙酯(DEAD)和偶氮二羧酸二异丙酯(DIAD))和三苯基膦可以用作试剂。
在利用酯化、酰胺化或脲化反应的每个步骤中,可以使用的试剂的实例包括酰卤,诸如酰氯或酰溴,以及活化的羧酸,诸如酸酐、活性酯或硫酸酯。羧酸活化剂的实例包括:碳二亚胺缩合剂,诸如1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐(WSCD);三嗪缩合剂,诸如4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基吗啉鎓氯化物-n-水合物(DMT-MM);碳酸酯缩合剂,诸如1,1-羰基二咪唑(CDI);二苯基磷酰叠氮化物(DPPA);苯并三唑-1-基氧基-三二甲基氨基磷鎓盐(BOP试剂);2-氯-1-甲基-碘化吡啶鎓(Mukaiyama试剂);亚硫酰氯;卤代甲酸低级烷基酯,诸如氯甲酸乙酯;O-(7-氮杂苯并三唑-1-基)-N,N,N’,N’-四甲基脲鎓六氟磷酸盐(HATU);硫酸;及其组合。在使用碳二亚胺缩合剂的情况下,向反应中添加添加剂诸如1-羟基苯并三唑(HOBt)、N-羟基琥珀酰亚胺(HOSu)或二甲基氨基吡啶(DMAP)可能是有益的。
在利用偶联反应的每个步骤中,可以使用的金属催化剂的实例包括钯化合物,诸如乙酸钯(II)、四(三苯基膦)钯(0)、二氯双(三苯基膦)钯(II)、二氯双(三乙基膦)钯(II)、三(二亚苄基丙酮)二钯(0)、1,1′-双(二苯基膦基)二茂铁氯化钯(II)和乙酸钯(II);镍化合物,诸如四(三苯基膦)镍(0);铑化合物,诸如三(三苯基膦)氯化铑(III);钴化合物;铜化合物,诸如氧化铜和碘化亚铜(I);和铂化合物。向反应中添加碱也可能是有益的。这种碱的实例包括无机碱和碱性盐。
在利用硫代羰基化反应的每个步骤中,通常将五硫化二磷用作硫代羰基化剂。可以使用具有1,3,2,4-二噻二磷杂丁环-2,4-二硫化物结构的试剂,诸如2,4-双(4-甲氧基苯基-1,3,2,4-二噻二磷杂丁环-2,4-二硫化物)(劳森试剂)代替五硫化二磷。
在利用Wohl-Ziegler反应的每个步骤中,可以使用的卤化剂的实例包括N-碘琥珀酰亚胺、N-溴琥珀酰亚胺(NBS)、N-氯琥珀酰亚胺(NCS)、溴和硫酰氯。可以通过进一步加入自由基引发剂,诸如热、光、过氧化苯甲酰或偶氮二异丁腈来加速反应。
在利用羟基的卤化反应的每个步骤中,可以使用的卤化剂的实例包括氢卤酸或无机酸的酰卤;实例包括用于氯化的盐酸、亚硫酰氯和氧氯化磷,以及用于溴化的48%氢溴酸。另外,还可以使用通过三苯基膦和四氯化碳或四溴化碳等的作用从醇获得烷基卤化物的方法。或者,也可以使用通过两步反应合成烷基卤化物的方法,所述两步反应包括将醇转化为磺酸酯,然后与溴化锂、氯化锂或碘化钠反应。
在利用Arbuzov反应的每个步骤中,可以使用的试剂的实例包括烷基卤化物,诸如溴乙酸乙酯;亚磷酸酯,诸如亚磷酸三乙酯和亚磷酸三(异丙基酯)。
在利用砜酯化反应的每个步骤中,所使用的磺酰化剂的实例包括甲磺酰氯、对甲苯磺酰氯、甲磺酸酐和对甲苯磺酸酐和三氟甲磺酸酐。
在利用水解反应的每个步骤中,可以将酸或碱用作试剂。在进行叔丁基酯的酸水解反应的情况下,可以添加诸如甲酸、三乙基硅烷等的试剂以还原性地捕集副产物叔丁基阳离子。
在利用脱水反应的每个步骤中,可以使用的脱水剂的实例包括硫酸、五氧化二磷、氧氯化磷、N,N′-二环己基碳二亚胺、氧化铝和多磷酸。
在另一个优选实施方案中,可以提及由下式(III)表示的阳离子脂质(在下文中也称为“化合物(III)”)。由下式表示的化合物:
其中
n1为2至6的整数,
n2为0至2的整数,
n3为0至2的整数,
L为-C(O)O-或-NHC(O)O-,
Ra为直链C5-13烷基、直链C13-17烯基或直链C17二烯基,
Rb为直链C2-9烷基,
Rc为氢原子或直链C2-9烷基,
Rd为氢原子或直链C2-9烷基,
Re为直链C2-9烷基,并且
Rf为直链C2-9烷基,
或其盐。
更优选地,可以提及以下以阳离子脂质表示的结构式。
及其盐。
在上述阳离子脂质中,更优选由以下结构式表示的阳离子脂质。
及其盐。
化合物(III)可以例如通过以下制备方法来制造。特别地,根据所需化合物(III)的结构,可以在酯化过程中使用适当的起始物质合成具有所需结构的化合物(I)。化合物(III)的盐可以通过与无机碱、有机碱、有机酸、碱性或酸性氨基酸适当混合而获得。
在上述制备方法的每个步骤的反应中使用的起始物质和试剂以及反应条件可以与上述化合物(II)的制备方法中所述的那些相同。
在另一个实施方案中,可以提及由以下结构式表示并描述于WO2011/153493中的阳离子脂质。
及其盐。
在上述阳离子脂质中,更优选由以下结构式表示的阳离子脂质。
及其盐。
在另一个实施方案中,可以提及由以下结构式表示并描述于WO 2013/126803中的阳离子脂质。
及其盐。
在上述阳离子脂质中,更优选由以下结构式表示的阳离子脂质。
及其盐。
在另一个实施方案中,可以提及通过Dong等人(Proc Natl Acad Sci U S A.2014年4月15日;111(15):5753)中所述的以下方案合成的阳离子脂质K-E12、H-A12、Y-E12、G-O12、K-A12、R-A12、cKK-E12、cPK-E12、PK1K-E12、PK500-E12、cQK-E12、cKK-A12、KK-A12、PK-4K-E12、cWK-E12、PK500-O12、PK1K-O12、cYK-E12、cDK-E12、cSK-E12、cEK-E12、cMK-E12、cKK-O12、cIK-E12、cKK-E10、cKK-E14和cKK-E16。
在上述阳离子脂质中,更优选cKK-E12、cKK-E14。
在另一个实施方案中,可以提及通过Love KT等人(Proc Natl Acad Sci U SA.2010年5月25日;107(21):9915)中所述的以下方案合成的阳离子脂质C14-98、C18-96、C14-113、C14-120、C14-120、C14-110、C16-96和C12-200。
在上述阳离子脂质中,更优选C14-110、C16-96和C12-200。
在一个特别优选的实施方案中,可以提及由下式(I)表示的阳离子脂质(在下文中也称为“化合物(I)”)。
其中
L1为C1-22亚烷基、C2-22亚烯基或C3-22亚二烯基,
n为0或1的整数,
R1为
(1)氢原子,
(2)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(3)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(4)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
R2为-CH2-O-CO-R5、-CH2-CO-O-R5或-R5,
R3为-CH2-O-CO-R6、-CH2-CO-O-R6或-R6,
R4为氢原子、-CH2-O-CO-R7、-CH2-CO-O-R7或-R7,
R5、R6和R7各自独立地为
(1)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(2)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(3)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,并且
R8和R9各自独立地为C1-6烷基,
或其盐。
L1为C1-22亚烷基、C2-22亚烯基或C3-22亚二烯基。
L1优选为C1-22亚烷基。
L1更优选为C1-12亚烷基。
L1进一步优选为C1-6亚烷基。
n为0或1的整数。
n优选为1的整数。
R1为
(1)氢原子,
(2)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(3)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(4)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代。
R1优选为
(1)氢原子,
(2)直链C1-22烷基(优选直链C6-12烷基),其任选地被一个或两个直链C1-22烷基(优选直链C6-12烷基)取代,或
(3)直链C2-22烯基(优选直链C6-12烯基),其任选地被一个或两个直链C2-22烯基(优选直链C6-12烯基)取代。
R1特别优选为氢原子。
R2为-CH2-O-CO-R5、-CH2-CO-O-R5或-R5。
R2优选为-CH2-O-CO-R5或-R5。
R2更优选为-CH2-O-CO-R5。
R3为-CH2-O-CO-R6、-CH2-CO-O-R6或-R6。
R3优选为-CH2-O-CO-R6或-R6。
R3更优选为-CH2-O-CO-R6。
R4为氢原子、-CH2-O-CO-R7、-CH2-CO-O-R7或-R7。
R4优选为氢原子或-CH2-O-CO-R7。
R4更优选为-CH2-O-CO-R7。
R5、R6和R7各自独立地为
(1)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(2)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(3)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代。
R5、R6和R7优选各自独立地为
(1)直链C1-22烷基(优选直链C4-18烷基),其任选地被一个或两个直链C1-22烷基(优选直链C1-10烷基)取代,
(2)直链C2-22烯基(优选直链C4-18烯基),或
(3)直链C3-22二烯基(优选直链C4-18二烯基)。
R5、R6和R7更优选各自独立地为
(1)直链C1-22烷基(优选直链C4-18烷基),其任选地被一个或两个直链C1-22烷基(优选直链C1-10烷基)取代,或
(2)直链C2-22烯基(优选直链C4-18烯基)。
R8和R9各自独立地为C1-6烷基。
R8和R9各自独立地为C1-3烷基(优选甲基)。
优选地,化合物(I)为上述式(I)的化合物,其中
L1为C1-22亚烷基(优选C1-12亚烷基,更优选C1-6亚烷基),
n为1的整数,
R1为
(1)氢原子,
(2)直链C1-22烷基(优选直链C6-12烷基),其任选地被一个或两个直链C1-22烷基(优选直链C6-12烷基)取代,或
(3)直链C2-22烯基(优选直链C6-12烯基),其任选地被一个或两个直链C2-22烯基(优选直链C6-12烯基)取代,
R2为-CH2-O-CO-R5或-R5,
R3为-CH2-O-CO-R6或-R6,
R4为氢原子或-CH2-O-CO-R7,
R5、R6和R7各自独立地为
(1)直链C1-22烷基(优选直链C4-18烷基),其任选地被一个或两个直链C1-22烷基(优选直链C1-10烷基)取代,
(2)直链C2-22烯基(优选直链C4-18烯基),或
(3)直链C3-22二烯基(优选直链C4-18二烯基),并且
R8和R9各自独立地为C1-6烷基(优选C1-3烷基,特别优选甲基)。
更优选地,化合物(I)为上述式(I)的化合物,其中
L1为C1-12亚烷基(优选C1-6亚烷基),
n为1的整数,
R1为氢原子,
R2为-CH2-O-CO-R5,
R3为-CH2-O-CO-R6,
R4为-CH2-O-CO-R7,
R5、R6和R7各自独立地为
(1)直链C1-22烷基(优选直链C4-18烷基),其任选地被一个或两个直链C1-22烷基(优选直链C1-10烷基)取代,
(2)直链C2-22烯基(优选直链C4-18烯基),或
(3)直链C3-22二烯基(优选直链C4-18二烯基),并且
R8和R9各自独立地为C1-6烷基(优选C1-3烷基,特别优选甲基)。
更优选地,化合物(I)为上述式(I)的化合物,其中
L1为C1-6亚烷基,
n为1的整数,
R1为氢原子,
R2为-CH2-O-CO-R5,
R3为-CH2-O-CO-R6,
R4为-CH2-O-CO-R7,
R5、R6和R7各自独立地为
(1)直链C1-22烷基(优选直链C4-18烷基),其任选地被一个或两个直链C1-22烷基(优选直链C1-10烷基)取代,或
(2)直链C2-22烯基(优选直链C4-18烯基),并且
R8和R9各自独立地为C1-3烷基(优选甲基)。
上述每个结构式表示的化合物的盐优选为药理学上可接受的盐。其实例包括与无机碱的盐(例如,碱金属盐,诸如钠盐、钾盐等;碱土金属盐,诸如钙盐、镁盐等;铝盐,铵盐);与有机碱的盐(例如,与三甲胺、三乙胺、吡啶、甲基吡啶、乙醇胺、二乙醇胺、三乙醇胺、缓血酸胺[三(羟甲基)甲胺]、叔丁胺、环己胺、苄胺、二环己胺、N,N-二苄基乙二胺的盐);与无机酸的盐(例如,与氢氟酸、盐酸、氢溴酸、碘化氢酸、硝酸、硫酸、磷酸的盐);与有机酸的盐(与甲酸、乙酸、三氟乙酸、邻苯二甲酸、富马酸、草酸、酒石酸、马来酸、柠檬酸、琥珀酸、苹果酸、甲磺酸、苯磺酸、对甲苯磺酸的盐);与碱性氨基酸的盐(与精氨酸、赖氨酸、鸟氨酸的盐);或与酸性氨基酸的盐(与天冬氨酸、谷氨酸的盐)。
本发明脂质纳米粒子中存在的阳离子脂质与总脂质的比率(mol%)为例如约10%至约80%,优选约20%至约70%,更优选约40%至约60%;然而,该比率不限于这些。
也可以仅使用上述阳离子脂质中的一种,或者可以组合使用其两种或更多种。当使用多种阳离子脂质时,整个阳离子脂质的比率优选如上所述。
(c)非阳离子脂质
在本说明书中,“非阳离子脂质”是指除阳离子脂质之外的脂质,并且是在选定pH诸如生理pH等下不具有净正电荷的脂质。在本发明的脂质纳米粒子中使用的非阳离子脂质的实例包括磷脂、类固醇、PEG脂质等。
为了增强编码CAR或外源性TCR的核酸到靶免疫细胞中的递送,对磷脂没有特别限制,只要其稳定地维持核酸并且不抑制与细胞膜(质膜和细胞器膜)的融合即可。例如,可以提及磷脂酰胆碱、磷脂酰乙醇胺、磷脂酰丝氨酸、磷脂酰肌醇、磷脂酸、棕榈酰油酰磷脂酰胆碱、溶血磷脂酰胆碱、溶血磷脂酰乙醇胺、二棕榈酰磷脂酰胆碱、二油酰磷脂酰胆碱、二硬脂酰磷脂酰胆碱、二亚麻酰磷脂酰胆碱等。
优选的磷脂包括二硬脂酰磷脂酰胆碱(DSPC)、二油酰磷脂酰胆碱(DOPC)、二棕榈酰磷脂酰胆碱(DPPC)、二油酰磷脂酰甘油(DOPG)、棕榈酰油酰磷脂酰甘油(POPG)、二棕榈酰磷脂酰甘油(DPPG)、二油酰-磷脂酰乙醇胺(DOPE)、棕榈酰油酰磷脂酰胆碱(POPC)、棕榈酰油酰-磷脂酰乙醇胺(POPE)和二油酰磷脂酰乙醇胺4-(N-马来酰亚胺甲基)-环己烷-1-羧酸酯(DOPE-mal),更优选DOPC、DPPC、POPC和DOPE。
本发明的脂质纳米粒子中存在的磷脂与总脂质的比率(mol%)可以是例如约0%至约90%,优选约5%至约30%,更优选约8%至约15%。
可以仅使用上述磷脂中的一种,或者可以组合使用其两种或更多种。当使用多种磷脂时,整个磷脂的比率优选如上所述。
作为类固醇,可以提及胆固醇、5α-胆甾烷醇、5β-粪甾醇、胆固醇基-(2’-羟基)-乙醚、胆固醇基-(4′-羟基)-丁醚、6-酮胆甾烷醇、5α-胆甾烷、胆甾烯酮、5α-胆甾烷酮、5β-胆甾烷酮和癸酸胆固醇酯,优选胆固醇。
当存在类固醇时,本发明的脂质纳米粒子中存在的类固醇与总脂质的比率(mol%)可以是例如约10%至约60%,优选约12%至约58%,更优选约20%至约55%。
可以仅使用上述类固醇中的一种,或者可以组合使用其两种或更多种。当使用多种类固醇时,整个类固醇的比率优选如上所述。
在本说明书中,“PEG脂质”是指聚乙二醇(PEG)和脂质的任何复合物。PEG脂质没有特别限制,只要其具有抑制本发明的脂质纳米粒子的聚集的作用即可。例如,可以提及与二烷氧基丙基缀合的PEG(PEG-DAA)、与二酰基甘油缀合的PEG(PEG-DAG)(例如,SUNBRIGHTGM-020(NOF公司))、与磷脂诸如磷脂酰乙醇胺缀合的PEG(PEG-PE)、与神经酰胺缀合的PEG(PEG-Cer)、与胆固醇缀合的PEG(PEG-胆固醇)或其衍生物或其混合物,mPEG2000-1,2-二-O-烷基-sn3-氨基甲酰基甘油酯(PEG-C-DOMG)、1-[8’-(1,2-二肉豆蔻酰基-3-丙氧基)-羧酰胺-3’,6-二氧辛烷]氨基甲酰基-ω-甲基-聚(乙二醇)(2KPEG-DMG)等。优选的PEG脂质包括PEG-DGA、PEG-DAA、PEG-PE、PEG-Cer及其混合物,更优选选自以下的PEG-DAA缀合物:PEG-二癸基氧基丙基缀合物、PEG-二月桂基氧基丙基缀合物、PEG-二肉豆蔻基氧基丙基缀合物、PEG-二棕榈基氧基丙基缀合物、PEG-二硬脂基氧基丙基缀合物及其混合物。
除了甲氧基之外,用于结合稍后描述的T细胞靶向配体的马来酰亚胺基、N-羟基琥珀酰亚胺基等可以用作PEG的自由端。例如,SUNBRIGHT DSPE-0201MA或SUNBRIGHT DSPE-0201MA(NOF)可以用作具有结合T细胞靶向配体的官能团的PEG脂质(在本说明书中有时称为“末端反应性PEG脂质”)。
本发明的脂质纳米粒子中存在的PEG脂质与总脂质的比率(mol%)可以是例如约0%至约20%,优选约0.1%至约5%,更优选约0.7%至约2%。
末端反应性PEG脂质在上述总PEG脂质中的比率(mol%)是例如约10%至约100%,优选约20%至约100%,更优选约30%至约100%。
可以仅使用一种上述的PEG脂质,或者可以组合使用其两种或更多种。当使用多种PEG脂质时,整个PEG脂质的比率优选如上所述。
本发明的脂质纳米粒子用于免疫细胞中的CAR或外源性TCR的基因转移和表达,所述免疫细胞特别是负责获得性免疫中的细胞免疫的T细胞;负责先天免疫的NK细胞、单核细胞、巨噬细胞、树突状细胞等;以及作为具有NK细胞特性的T细胞的NKT细胞。因此,本发明的脂质纳米粒子可以进一步含有配体,所述配体可以将脂质纳米粒子靶向到免疫细胞,特别是T细胞,以有效地递送至靶向的免疫细胞,特别是在体内。
(d)能够将脂质纳米粒子靶向至T细胞的配体
能够将本发明的脂质纳米粒子靶向至T细胞的配体没有特别限制,只要其可以特异性识别在T细胞中特异性或高度表达的表面分子即可。优选地,它包括含有针对CD3、CD4、CD8或CD28的抗体的一个或多个抗原结合结构域的那些,并且更优选地,它包括含有抗CD3抗体和/或抗CD28抗体的抗原结合结构域的那些。体内递送至T细胞的特别优选的实例是仅含有抗CD3抗体的抗原结合结构域的实例。在此,“抗原结合结构域”与构成上述CAR的抗原结合结构域同义。然而,由于需要将CAR制备为其编码核酸,因此存在限制,在许多情况下通常使用单链抗体。由于作为T细胞靶向配体的抗原结合结构域以蛋白质状态包含在本发明的脂质纳米粒子中,因此不仅可以使用单链抗体,而且也可以优选使用任何其他抗体片段,诸如完整的抗体分子,Fab、F(ab’)2、Fab′、Fv、还原抗体(rIgG)、dsFv、sFv、双抗体、三抗体等。可以优选使用不具有Fc部分的Fab’,尤其是用于体内递送至靶免疫细胞。这些抗体片段可以通过用还原剂(例如2-巯基乙醇、二硫苏糖醇)或肽酶(例如木瓜蛋白酶、胃蛋白酶、无花果蛋白酶)处理完整抗体(例如IgG)或通过基因重组操作来制备。
当靶向T细胞的配体是完整的抗体分子时,可以使用可商购的抗CD3、CD4、CD8、CD28抗体等,或者可以从产生抗体的细胞的培养物中分离出配体。另一方面,当配体是上述抗原结合结构域(抗体片段)中的任一个时,按照与获得编码构成所述CAR的抗原结合结构域的核酸相同的方式,分离编码抗原结合结构域的核酸,诸如抗CD3、CD4、CD8、CD28抗体等,并且可以使用所述核酸来重组产生抗原结合结构域。
在本发明的脂质纳米粒子中,靶向T细胞的配体可以任何方式结合至外壳,只要其存在于脂质纳米粒子的表面上即可。例如,当含有末端反应性PEG脂质作为非阳离子脂质时,可以将配体添加至PEG的末端。例如,可以通过使有马来酰亚胺基引入到末端的PEG脂质(例如,SUNBRIGHT DSPE-0200MA)与上述还原抗体的硫醇基反应来制备标记有配体(抗体)的脂质纳米粒子(有时称为“抗体-LNP”)。
当本发明的脂质纳米粒子用于向除T细胞以外的免疫细胞诸如NK细胞和树突状细胞进行基因转移时,即使脂质纳米粒子表面上不存用于靶向至那些免疫细胞的配体,脂质纳米粒子也可以有效地递送。它在脂质纳米粒子的表面上还可以具有针对在每个免疫细胞表面上表达的分子的合适的靶向配体。例如,在NK细胞的情况下,可以提及含有抗CD16和CD56抗体的抗原结合结构域的那些,但为非限制性的。
2.制备本发明的脂质纳米粒子
本发明的脂质纳米粒子可以例如通过US9,404,127中描述的方法来制备。当脂质纳米粒子进一步含有靶向T细胞的配体时,可以通过在制备脂质纳米粒子之后化学结合靶向T细胞的配体来制备。如WO2016/021683中所述,例如,制备上述组分(b)和(c)的有机溶剂溶液,将该有机溶剂溶液与水或(a)的缓冲溶液混合以制备脂质纳米粒子,然后化学结合靶向T细胞的配体以制备其。阳离子脂质、磷脂、胆固醇和PEG脂质的混合比(摩尔比)为例如40至60:0至20:0至50:0至5,但该比率不限于此。当将PEG脂质作为非阳离子脂质混合并且将靶向T细胞的配体添加至PEG的末端时,PEG脂质与配体的混合比(摩尔比)可以为例如20:1至1:20。上述PEG脂质可以以约10%至约100%的比率(mol%)含有末端反应性PEG。可以使用移液管、微流体混合系统(例如,Asia微流体系统(Syrris))或Nanoassemblr(PrecisionNanosystems)进行上述混合。可以通过凝胶过滤、透析或无菌过滤对获得的脂质粒子进行纯化。
有机溶剂溶液中的总脂质组分的浓度优选为0.5至100mg/mL。
作为有机溶剂,例如,可以提及甲醇、乙醇、1-丙醇、2-丙醇、1-丁醇、叔丁醇、丙酮、乙腈、N,N-二甲基甲酰胺、二甲基亚砜或其混合物。有机溶剂可以含有0至20%的水或缓冲溶液。作为缓冲溶液,可以提及酸性缓冲溶液(例如乙酸盐缓冲溶液、柠檬酸盐缓冲溶液)或中性缓冲溶液(例如4-(2-羟乙基)-1-哌嗪乙烷磺酸、(HEPE)缓冲溶液、三(羟甲基)氨基甲烷(Tris)缓冲溶液、磷酸盐缓冲溶液、磷酸盐缓冲生理盐水(PBS))。
在使用微流体混合系统进行混合的情况下,优选将1体积份的有机溶剂溶液与1至5体积份的水或缓冲溶液混合。另外,在所述系统中,混合物(有机溶剂溶液与水或缓冲溶液的混合溶液)的流动速率优选为0.1至10mL/min,温度优选为4至45℃。
当如上所述制备脂质粒子分散液时,可以通过将编码CAR或外源性TCR的核酸添加至水或缓冲溶液中来制备含有组分(a)至(d)的分散液。优选以使其在水中或缓冲溶液中的活性成分浓度为0.05至2.0mg/mL的方式添加核酸。
另外,本发明的脂质纳米粒子还可以通过用本身已知的方法将脂质粒子分散液与核酸混合来制备。
在本发明的脂质纳米粒子中,核酸的含量优选为1-20wt%。可以使用Quant-iTTM (Invitrogen)测量含量。在本发明的脂质纳米粒子中,可以基于在添加或不添加表面活性剂(例如Triton-X100)的情况下荧光强度的差异来计算核酸的包封率。
可以通过透析用水或缓冲溶液代替分散介质。对于透析,使用截留分子量为10至20K的超滤膜在4℃至室温下进行。透析可以重复进行。对于透析,可以使用切向流过滤。
如上所述获得的本发明的脂质纳米粒子中的核酸与脂质的比率(重量比)为约0.01至约0.2。
本发明的脂质纳米粒子的平均粒度优选为10至200nm。脂质粒子的平均粒度可以使用例如Zetasizer Nano ZS(Malvern Instruments)在自相关函数的累积量分析中计算。
3.引入有本发明的脂质纳米粒子的离体免疫细胞
本发明提供了一种通过以下方式制备表达CAR或外源性TCR的离体免疫细胞的方法:使从活生物体收集的免疫细胞(在本说明书中也称为“离体免疫细胞”)与本发明的脂质纳米粒子接触,并将编码CAR或外源性TCR的核酸引入T细胞;以及通过该方法获得的离体免疫细胞。如本文所用,“免疫细胞”没有特别限制,只要它是能够通过某些作用机制破坏靶细胞(致病细胞)诸如癌细胞等的细胞(即,免疫效应细胞)即可。其实例包括负责获得性免疫中的细胞免疫的T细胞;负责先天免疫的NK细胞、单核细胞、巨噬细胞、树突状细胞等;以及作为具有NK细胞特性的T细胞的NKT细胞。在一个优选实施方案中,免疫细胞可以是T细胞。从活生物体收集的T细胞在本说明书中也称为“离体T细胞”。在另一个优选实施方案中,免疫细胞可以负责先天免疫,诸如NK细胞、巨噬细胞、树突状细胞等。即使HLA类型匹配,T细胞也被认为具有相当大的因同种异体(allo)移植引起GVHD的风险,而allo-NK细胞等被认为不会引起GVHD。因此,制备各种HLA型allo离体免疫细胞允许现成使用。CAR-NK细胞描述于例如US2016/0096892,Mol Ther.25(8):1769-1781(2017)等中,CAR-树突状细胞、CAR-巨噬细胞等描述于例如WO 2017/019848,eLIFE.2018 e36688等中。
在另一方面,本发明提供了含有本发明的脂质纳米粒子的用于诱导CAR或外源性TCR的表达的组合物。
引入了本发明的脂质纳米粒子的免疫细胞(例如,T细胞)可以是分离的特定免疫细胞(例如,T细胞),或者例如是不均匀的细胞群,诸如淋巴细胞和淋巴细胞的祖细胞,包括多能细胞,只要它是含有免疫细胞(例如,T细胞)或其祖细胞的细胞群即可。在本发明中,“淋巴细胞”是指脊椎动物的免疫系统中白细胞的一种亚型。淋巴细胞的实例包括T细胞、B细胞和天然杀伤细胞(NK细胞),优选分离和纯化的T细胞。在本发明中,“T细胞”是在淋巴器官、外周血等中发现的白细胞的一种类型,并且是指以主要在胸腺中分化和成熟并且表达TCR为特征的一类淋巴细胞。可以用于本发明的T细胞的实例包括细胞毒性T细胞(CTL),其是CD8阳性细胞;辅助T细胞,其是CD4阳性细胞;调节性T细胞;和效应T细胞,并且优选是细胞毒性T细胞。
前述淋巴细胞可以从例如人类或非人类哺乳动物的外周血、骨髓和脐带血中收集。当将引入有本发明的脂质纳米粒子的离体免疫细胞(例如离体T细胞)用于治疗疾病诸如癌症时,优选从待治疗者或HLA类型与待治疗受试者的类型匹配的供体中收获细胞群。
包括多能细胞在内的淋巴细胞祖细胞的实例包括胚胎干细胞(ES细胞)、诱导多能干细胞(iPS细胞)、胚胎癌细胞(EC细胞)、胚胎生殖细胞(EG细胞)、造血干细胞、失去自我更新潜能的多能祖细胞(多能祖细胞:MMP)、普通骨髓-淋巴祖细胞(MLP)、骨髓祖细胞(MP)、粒细胞单核祖细胞(GMP)、巨噬细胞-树突状细胞祖细胞(MDP)、树突状细胞祖细胞(DCP)等。可以通过本身已知的方法将未分化的细胞诸如多能细胞等分化为各种免疫细胞,例如T细胞。
使离体免疫细胞与本发明的脂质纳米粒子接触的方法没有特别限制,例如,可以将本发明的脂质纳米粒子添加至用于免疫细胞的典型培养基中。或者,为了提高引入效率,例如,可以组合使用磷酸钙共沉淀法、PEG法、电穿孔法、显微注射法、脂质转染法等。
当本发明的脂质纳米粒子特别地含有编码外源性TCR的核酸作为活性成分时,从增加外源性TCR的表达、抑制错配TCR的出现或抑制自身反应性的角度出发,可以通过siRNA抑制由T细胞固有表达的内源性TCR α链和TCR β链的表达。当将上述核酸应用于该方法时,为了避免siRNA对外源性TCR的影响,编码TCR的核酸的碱基序列优选为与对应于抑制内源性TCRα和TCRβ链的表达的siRNA所作用的RNA的碱基序列不同的序列(密码子转换型序列)。其方法描述于例如WO 2008/153029中。通过将沉默突变引入编码TCR的天然获得的核酸或化学合成人工设计的核酸,可以产生上述碱基序列。或者,为了避免与内源性TCR链错配,可以将编码外源性TCR的核酸的部分或全部恒定区替换为源自人以外的动物例如小鼠的恒定区。
4.含有本发明的脂质纳米粒子或引入有脂质纳米粒子的离体免疫细胞的药物
本发明提供了含有本发明的脂质纳米粒子或引入有脂质纳米粒子的离体免疫细胞(例如,离体T细胞)的药物(以下简称为“本发明的药物”)。
(4-1.含有引入有本发明的脂质纳米粒子的离体免疫细胞的药物)
通过表达CAR或外源性TCR,引入有本发明的脂质纳米粒子的免疫细胞(例如,T细胞)可以特异性识别表达由CAR或外源性TCR特异性识别的表面抗原的细胞,并杀死它们(例如,诱导细胞凋亡)。因此,通过含有作为表面抗原的识别在疾病细胞诸如癌细胞中特异性表达或显示出增强表达的表面分子的CAR或外源性TCR的编码核酸作为活性成分,引入有本发明的脂质纳米粒子的离体免疫细胞可以用于预防或治疗疾病,诸如癌症等,并且可以安全地施用于哺乳动物(人类或其他哺乳动物(例如,小鼠、大鼠、仓鼠、兔、猫、狗、牛、绵羊、猴子,优选人类))。
(4-2.含有本发明的脂质纳米粒子的药物)
含有本发明的脂质纳米粒子的本发明药物优选通过将脂质纳米粒子与已知的药学上可接受的载体(包括赋形剂、稀释剂、填充剂、粘合剂、润滑剂、助流剂、崩解剂、表面活性剂等)和常规添加剂等混合而制备为药物组合物。赋形剂是本领域普通技术人员众所周知的,并且包括例如磷酸盐缓冲生理盐水(例如0.01M磷酸盐、0.138M NaCl、0.0027M KCl,pH 7.4);含有无机酸盐诸如盐酸盐、氢溴酸盐、磷酸盐、硫酸盐等的水溶液;生理盐水溶液;乙二醇、乙醇等的溶液;以及有机酸的盐诸如乙酸盐、丙酸盐、丙二酸盐、苯甲酸盐等。另外,也可以使用佐剂,诸如润湿剂或乳化剂,以及pH缓冲剂。另外,也可以使用制备佐剂,诸如悬浮剂、防腐剂、稳定剂和分散剂。或者,上述药物组合物可以是干燥形式,其在使用前用合适的无菌液体复溶。取决于组合物的制备形式,药物组合物可以口服或肠胃外全身性或局部给药(口服剂,诸如片剂、丸剂、胶囊、粉剂、颗粒剂、糖浆剂、乳剂、混悬剂等;肠胃外剂,诸如注射剂、滴注剂、外用制剂、栓剂等)。对于肠胃外给药,可以使用静脉内给药、皮内给药、皮下给药、直肠给药、经皮给药等。当以注射形式使用时,也可以添加可接受的缓冲剂、增溶剂、等渗剂等。
含有本发明的脂质纳米粒子的本发明药物的剂量例如在每剂量每1kg体重0.001mg至10mg编码CAR或外源性TCR的核酸的量的范围内。例如,当施用于人类患者时,对于体重为60kg的患者,剂量在0.0001至50mg的范围内。上述剂量是一个实例,该剂量可以根据所用核酸的类型、给药途径、给药受试者或患者的年龄、体重、症状等适当选择。
通过施用于哺乳动物(例如,人类或其他哺乳动物(例如,小鼠、大鼠、仓鼠、兔、猫、狗、牛、绵羊、猴),优选人类),含有本发明的脂质纳米粒子的本发明药物可以在动物体内的免疫细胞例如T细胞(在本说明书中也称为“体内免疫细胞”或“体内T细胞”)中诱导CAR或外源性TCR的表达。体内免疫细胞特异性识别表达由CAR或外源性TCR靶向的表面抗原的癌细胞等,并杀死患病细胞,从而显示出对该疾病的预防或治疗作用。
在含有引入有本发明的脂质纳米粒子的离体免疫细胞作为活性成分的药物的情况下,可以在施用于受试者之前使用适当的培养基和/或刺激分子来培养和/或刺激免疫细胞。刺激分子包括但不限于细胞因子、合适的蛋白质和其他组分。在T细胞的情况下,细胞因子的实例包括IL-2、IL-7、IL-12、IL-15、IFN-γ等,并且优选地,可以使用IL-2。尽管培养基中的IL-2的浓度没有特别限制,但其例如优选为0.01至1×105U/mL,更优选为1至1×104U/mL。合适的蛋白质的实例包括CD3配体、CD28配体和抗IL-4抗体。也可以添加淋巴细胞刺激因子,诸如凝集素。另外,可以将血清或血浆添加至培养基中。尽管其添加至培养基的量没有特别限制,但可以列举0体积%至20体积%,并且可以根据培养阶段改变血清或血浆的使用量。例如,可以逐步地降低血清或血浆浓度。血清和血浆可以源自于自身或非自身,但是从安全性的角度出发,优选源自于自身的那些。
优选将含有引入有本发明脂质纳米粒子的离体免疫细胞作为活性成分的药物肠胃外施用于受试者。肠胃外给药方法包括静脉内、动脉、肌内、腹膜内和皮下给药。尽管根据受试者的病况、体重、年龄等选择剂量,但对60kg体重的受试者进行给药以一般获得每剂量1×106-1×1010个细胞,优选1×107-1×109个细胞,更优选5×107-5×108个细胞。药物可以单剂量或多剂量给药。含有引入有本发明的脂质纳米粒子的离体免疫细胞作为活性成分的本发明药物可以是适合于肠胃外给药的已知形式,诸如注射剂或输注剂。药物可以适当地含有药学上可接受的赋形剂。药学上可接受的赋形剂包括上述那些。药物可以含有生理盐水、磷酸盐缓冲生理盐水(PBS)、培养基等以稳定地维持细胞。培养基不受特别限制,并且其实例包括但不限于RPMI、AIM-V、X-VIVO10等。另外,出于稳定化的目的,可以将药学上可接受的载体(例如人血清白蛋白)、防腐剂等添加至药物。
本发明的药物可以是用于癌症的预防或治疗药物。对作为本发明药物的应用靶标的癌症没有特别限制。其实例包括但不限于急性淋巴细胞癌、肺泡横纹肌肉瘤、膀胱癌、骨癌、脑癌(例如髓母细胞瘤)、乳腺癌、肛门、肛管或肛门直肠癌、眼癌、肝内胆管癌、关节癌、子宫颈癌、胆囊癌或胸膜癌、鼻癌、鼻腔癌或中耳癌、口腔癌、外阴癌、慢性髓细胞癌、结肠癌、食道癌、子宫颈癌、纤维肉瘤、胃肠类癌、头颈癌(例如头颈鳞状细胞癌)、下咽癌、肾癌、喉癌、白血病(例如急性淋巴母细胞白血病、急性淋巴细胞白血病、慢性淋巴细胞白血病、急性髓细胞白血病)、液体肿瘤、肝癌、肺癌(例如非小细胞肺癌)、淋巴瘤(例如霍奇金淋巴瘤、非霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤)、恶性间皮瘤、肥大细胞瘤、黑素瘤、多发性骨髓瘤、鼻咽癌、卵巢癌、胰腺癌、腹膜癌、大网膜癌和肠系膜癌;咽癌、前列腺癌、直肠癌、肾癌、皮肤癌、小肠癌、软组织癌、实体肿瘤、胃癌、睾丸癌、甲状腺癌、输尿管癌等。
下面通过参考实施例更详细地解释本发明,所述实施例仅仅是示例性的,并不限制本发明。
[实施例]
实施例1
(抗体的还原处理)
将9.21mg/ml抗CD3抗体(Bio X Cell)(111μl)与10mM DTT水溶液(12.3μl)混合。类似地,将6.73mg/ml IgG2a抗体(Bio X Cell)(149μl)与10mM DTT水溶液(16.6μl)混合。将每种抗体和DTT的混合物通过涡旋混合以在室温下进行反应30分钟。通过HPLC(柱:TSKgel G2000SWXL 7.8mm×30cm,TOSOH,流动相:PBS)分离反应混合物,得到含有还原抗体的级分溶液。使用Amicon 0.5ml-10K将级分溶液超离心。分别通过在230nm处的吸光度和与N-(7-二甲基氨基-4-甲基香豆素-3-基)马来酰亚胺(DACM)的荧光比色反应,测量浓缩物中抗体蛋白和硫醇基的浓度。还原的抗CD3抗体的产量为176μl,蛋白质浓度为1.75mg/ml,硫醇基浓度为5.14μM,还原的IgG2a抗体的产量为86μl,蛋白质浓度为5.19mg/ml,硫醇基浓度为45.1μM。
实施例2
(制备马来酰亚胺-LNP)
将脂质混合物(阳离子脂质∶DPPC∶胆固醇∶SUNBRIGHTGM-020∶SUNBRIGHT DSPE-020MA=60∶10.6∶28∶1.4∶1,摩尔比)溶解在90%EtOH、10%水中,得到7.0mg/ml脂质溶液。作为阳离子脂质,以59.1∶0.9(摩尔比)混合并使用WO 2016/021683中描述的3-戊基辛酸3-((5-(二甲基氨基)戊酰基)氧基)-2,2-双(((3-戊基辛酰基)氧基)甲基)丙基酯(化合物7),以及N,N,N-三甲基-5-氧代-5-(3-((3-戊基辛酰基)氧基)-2,2-双(((3-戊基辛酰基)氧基)甲基)丙氧基)戊烷-1-碘化铵(化合物8)。将编码具有4-1BB和CD3ζ作为细胞内信号转导结构域的靶向CD19的CAR的mRNA溶解在10mM 2-吗啉代乙磺酸(MES)缓冲液(pH 5.0)中,得到0.2mg/ml核酸溶液。在室温下,通过Nanoassemblr装置(Precision Nanosystems)以3ml/min:6ml/min的流动速率比混合所得的脂质溶液和核酸溶液,得到含有组合物的分散液。将所得的分散液使用Slyde-A-Lyzer(20k级分分子量,Thermo Scientific)在室温下对水透析1小时,并在4℃下对PBS透析48小时。接着,将透析液通过0.2μm注射过滤器(Iwaki)过滤并保存在4℃。
实施例3
(还原抗体与马来酰亚胺-LNP的结合反应)
将马来酰亚胺-LNP分散液与还原抗体溶液混合至1/20摩尔浓度的还原抗体比马来酰亚胺,并使其在室温下静置4小时。之后,将混合物在4℃下保存直至纯化步骤。
实施例4
(抗体-LNP的凝胶过滤纯化)
将还原抗体和马来酰亚胺-LNP的反应混合物装载在凝胶过滤柱Sepharose CL-4B(目录号17-0150-01/GE Healthcare)上,并用D-PBS(-)作为流动相进行分离。接着,测量每个级分的蛋白质浓度以鉴定含有感兴趣的抗体-LNP的级分。将抗体-LNP通过0.2μm注射过滤器过滤并保存在4℃。
实施例5
(CD8+T细胞的离体转染)
从C57BL/6J小鼠收集脾脏,并将其分散在ACK裂解缓冲液(Biosource)中,得到小鼠脾细胞。将获得的小鼠脾细胞在含有1ng/ml白介素7和2μg/ml伴刀豆球蛋白A的完全RPMI1640培养基中培养2天,并通过使用Ficoll密度梯度离心去除死细胞并使用CD8阴性分离试剂盒(Stemcell Technologies)处理来分离小鼠CD8+T细胞。将获得的小鼠CD8+T细胞分散并在含有10ng/ml白介素2和抗体-LNP的完全RPMI 1640培养基中培养,以用CAR或外源性TCR转染小鼠CD8+T细胞。
以相同的方式,将CD8+T细胞与购买的培养的人原代T细胞分离,并用CAR或外源性TCR转染人CD8+T细胞。
实施例6
(CAR-T细胞的体外细胞毒性评估)
将强力表达CD19的人慢性骨髓性白血病细胞系K562细胞(待评估细胞毒性的细胞)用膜染料PKH-26(Sigma-Aldrich)标记,用含有10%胎牛血清的RPMI培养基洗涤,以1×105个细胞/ml分散于培养基中并培养。将标记的细胞毒性评估细胞分散于96孔板中并进行培养。将细胞与CAR-T细胞混合,在37℃下培养3小时,用Annexin V-Brilliant Violet 421(BioLegend)染色,并进行流式细胞术以对凋亡细胞进行定量。
实施例7
(体内抗癌活性评估测试)
将稳定表达荧光素酶的K562-CD19细胞从尾静脉施用于6周龄的NOD-SCID小鼠,并且将其饲养1周以制备小鼠血液癌症模型。接着,通过尾静脉施用,每周一次施用1×106个通过使用抗体-LNP离体转染编码CAR的核酸而获得的人CAR-T细胞,持续3周。通过使用体内发光成像系统IVIS(PerkinElmer)的测量来评估CAR-T细胞对癌细胞的减少。
实施例8
(使用阳离子脂质制备马来酰亚胺-LNP)
将脂质混合物(阳离子脂质∶DPPC∶胆固醇∶SUNBRIGHTGM-020∶SUNBRIGHT DSPE-020MA=60∶10.6∶28∶1.4∶1,摩尔比)溶解在90%EtOH、10%25mM醋酸盐缓冲液pH 4.0中,得到10mg/ml脂质溶液。作为阳离子脂质,使用(9Z)-十四-9-烯酸3-((5-(二甲基氨基)戊酰基)氧基)-2,2-双(((9Z)-十四-9-烯酰氧基)甲基)丙酯(化合物12)、(9Z,9’Z)双-十四-9-烯酸2-(((4-(二甲基氨基)丁酰基)氧基)甲基)-2-((十二烷酰基氧基)甲基)丙烷-1,3-二酯(化合物21)和双癸酸2-(((4,5-二丁基壬酰基)氧基)甲基)-2-(((5-(二甲基氨基)戊酰基)氧基)甲基)丙烷-1,3-二酯(化合物35)。将编码靶向CD19的CAR的pcDNA3.1-hCD19CAR溶于10mM 2-吗啉代乙磺酸(MES)缓冲液(pH 5.5)中,得到0.2mg/ml核酸溶液。通过将WO2013/126712中引用的CD19 IgG4 28z序列整合到pcDNA3.1(Thermo Fisher Scientific)的多克隆位点中来产生pcDNA3.1-hCD19CAR。在室温下,通过Nanoassemblr装置(PrecisionNanosystems)以3ml/min∶6ml/min的流动速率比混合所得的脂质溶液和核酸溶液,得到含有组合物的分散液。将所得的分散液使用Slyde-A-Lyzer(20k级分分子量,ThermoScientific)在室温下对水透析1小时,并在4℃下对PBS透析48小时。接着,将透析液通过0.2μm注射过滤器(Iwaki)过滤并保存在4℃。
(测量马来酰亚胺-LNP的核酸浓度,并计算假定的马来酰亚胺浓度)
将马来酰亚胺-LNP溶解在0.5%Triton X-100中,并使用Quant-iTTM PicoGreenTMdsDNA分析试剂盒(Thermo Fisher Scientific)测量pDNA浓度。将在未添加Triton X-100的情况下测量的pDNA浓度作为未包封在LNP中的pDNA的浓度,计算出pDNA在LNP中的包封率。通过将测得的pDNA浓度乘以马来酰亚胺-PEG-脂质(DSPE-020MA)的装料比来计算假定的马来酰亚胺浓度。所得值示于表1。
[表1]
(两种混合的还原抗体与马来酰亚胺-LNP的结合反应)
将用DTT还原的等量的抗人CD3抗体(BE0001-2,BioXCell)和抗人/猴CD28抗体(BE0248,BioXCell)以与马来酰亚胺-LNP的马来酰亚胺为1/20的摩尔量混合。表2显示了马来酰亚胺-LNP和还原抗体的浓度和体积。使混合物在室温下静置4小时,然后在4℃下保存直至纯化步骤。
[表2]
(抗体-LNP的凝胶过滤纯化)
将还原抗体和马来酰亚胺-LNP的反应混合物装载在凝胶过滤柱Sepharose CL-4B(目录号17-0150-01/GE Healthcare)上,并用D-PBS(-)作为流动相进行分离。接着,测量每个级分的蛋白质浓度以鉴定含有感兴趣的抗体-LNP的级分。将抗体-LNP通过0.2μm注射过滤器过滤并保存在4℃。通过Zetasizer Nano ZS(Malvern Panalytical)测量获得的抗体-LNP的粒度。分别使用Quant-iTTM PicoGreenTM dsDNA分析试剂盒(Thermo FisherScientific)和ATTO-TAGTM FQ胺衍生试剂盒(Thermo Fisher Scientific)测量核酸和抗体蛋白的浓度。每个分析结果的值示于表3。
[表3]
实施例9
(使用抗体-LNP对培养的人原代T细胞进行CD19 CAR转染测试)
用培养基以1.1×106个细胞/ml制备人Pan-T细胞(AccuCell人外周血Pan-T细胞,阴性选择),并以90μl/孔接种在96孔板中。将补充有浓度为30ng/ml的重组IL-2(ThermoFisher Scientific)的X-VIVO10(Lonza)用作培养基。接着,将10μl用PBS稀释至30μg/mlpcDNA3.1-hCD19CAR浓度的抗体-LNP添加至培养基中,并将细胞在5%CO2培养箱中于37℃培养3天和6天。
(通过流式细胞术评估CD19CAR表达)
将在96孔板中培养的培养的人原代T细胞收集在1.5ml试管中,加入重组人CD19蛋白,Fc Chimera Active,Biotin(Abcam)(2μl),将混合物在冰上静置30分钟。接着,加入添加有200μl 1%FBS的CellWash(BD),通过以300×g离心5分钟将混合物洗涤两次,除去上清液,将细胞分散在100μl 1%FBS,Cell Wash中。向细胞分散液中加入0.2μl BrilliantViolet 421链霉亲和素,并在通过移液混合后,将分散液在冰上静置30分钟。将染色的细胞用200μl的1%FBS Cell Wash洗涤3次并离心,过滤,分散在200μl的1%FBS Cell Wash中,并通过LSRFortessa(BD)进行流式细胞术分析。
通过流式细胞术分析对经hCD3/hCD28-化合物12-pcDNA3.1-hCD19CAR转染的培养的人原代T细胞的CD19 CAR表达分析结果如图1所示。加入抗体-LNP后第3天和第6天的CD19CAR阳性率分别为51.9%和41.7%,与通过病毒载体进行基因转移相比,获得的CAR阳性细胞具有足够的效率。
通过流式细胞术分析对经hCD3/hCD28-化合物21-pcDNA3.1-hCD19CAR和hCD3/hCD28-化合物35-pcDNA3.1-hCD19CAR转染的培养的人原代T细胞的CD19 CAR表达分析结果如图2所示。加入抗体-LNP后第3天的CD19 CAR阳性率分别为5.12%和47.0%。
实施例10
(通过抗体-LNP对经CD19 CAR转染的培养的人原代T细胞的癌症细胞毒性评估)
将用DELFIA细胞毒性分析试剂盒(Perkin Elmer)标记的人前B细胞系NALM-6和人Burkitt淋巴瘤细胞系Daudi作为靶细胞以1×104个细胞/100μl/孔的细胞密度接种在96孔U底板中。作为培养基,使用含10%FBS的RPMI(不含酚红)。接着,通过分散在100μl培养基中使效应细胞与靶细胞的细胞数比为0比16,添加通过另一部分所述的方法通过hCD3/hCD28-化合物12-pcDNA3.1-hCD19CAR经CD19CAR转染的培养的人原代T细胞(添加抗体-LNP后3天的CD19CAR阳性率:19%)作为效应细胞。将靶细胞和效应细胞混合后3小时,收集20μl的培养上清液。将铕溶液(Eu)(20μl)添加至收集的培养上清液中,并根据从受损靶细胞释放的螯合剂TDA和Eu的复合物发射的荧光强度计算细胞毒性率。
图3显示了由于添加了用CD19 CAR转染的人原代T细胞而导致的Nalm-6和Daudi的细胞毒性率。
实施例11
(制备还原Fab’)
使用Pierce F(ab′)2制备试剂盒(Thermo Fisher Scientific)从抗小鼠CD3ε抗体(BE0001-1,BioXCell)和抗小鼠CD28抗体(BE0015-1,BioXCell)制备与马来酰亚胺-LNP缀合的还原Fab′。从7.86mg/ml抗小鼠CD3ε抗体(0.5ml)获得1ml1.75mg/ml F(ab’)2。从3.86mg/ml抗小鼠CD28抗体(0.5ml)获得0.62ml的0.97mg/ml F(ab’)2。将每种F(ab’)2与作为还原剂的2-氨基乙硫醇对甲苯磺酸盐以40mM的浓度混合,并将混合物在37℃下静置1小时。将所获得的Fab’通过ZebaSpin Desalting Columns.7K MWCO-0.5ml(Thermo FischerScientific)纯化,并保存在4℃下,直到与马来酰亚胺-LNP反应。分别通过在230nm处的吸光度和与N-(7-二甲基氨基-4-甲基香豆素-3-基)马来酰亚胺(DACM)的荧光比色反应,测量Fab’蛋白和硫醇基的浓度。
实施例12
(还原Fab’与马来酰亚胺-LNP的结合反应)
将还原抗小鼠CD3εFab’和抗小鼠CD28 Fab’以与通过上述方法制备的马来酰亚胺-LNP的马来酰亚胺为1/20的摩尔量混合。使混合物在室温下静置4小时,然后在4℃下保存直至纯化步骤。
实施例13
(还原Fab’-LNP的凝胶过滤纯化)
将还原Fab’和马来酰亚胺-LNP的反应混合物装载在凝胶过滤柱Sepharose CL-4B(目录号17-0150-01/GE Healthcare)上,并用D-PBS(-)作为流动相进行分离。接着,测量每个级分的蛋白质浓度以鉴定含有感兴趣的Fab’-LNP的级分。将Fab’-LNP通过0.2μm注射过滤器过滤并保存在4℃。通过Zetasizer Nano ZS(Malvern Panalytical)测量获得的抗体-LNP的粒度。分别使用Quant-iTTM PicoGreenTM dsDNA分析试剂盒(Thermo FisherScientific)和ATTO-TAGTM FQ胺衍生试剂盒(Thermo Fisher Scientific)测量核酸和抗体蛋白的浓度。
工业适用性
本发明的脂质纳米粒子可以有效地引入CAR或外源性TCR,并且不仅可以离体而且可以体内选择性地引入T细胞,因此可以以低的生产成本提供CAR-T或TCR-T细胞疗法。另外,由于不使用病毒载体,因此可以避免病毒蛋白的抗原性问题,作为癌症免疫疗法的新平台极为有用。
本申请是基于在日本提交的专利申请第2017-252616号(提交日:2017年12月27日),其内容通过引用全部结合于此。
Claims (34)
1.一种脂质纳米粒子,其包含以下(a)至(c):
(a)编码嵌合抗原受体或外源性T细胞受体的核酸;
(b)阳离子脂质;和
(c)非阳离子脂质。
2.根据权利要求1所述的脂质纳米粒子,其中前述阳离子脂质为式(I)表示的化合物或其盐:
其中
L1为C1-22亚烷基、C2-22亚烯基或C3-22亚二烯基,
n为0或1的整数,
R1为
(1)氢原子,
(2)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(3)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(4)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
R2为-CH2-O-CO-R5、-CH2-CO-O-R5或-R5,
R3为-CH2-O-CO-R6、-CH2-CO-O-R6或-R6,
R4为氢原子、-CH2-O-CO-R7、-CH2-CO-O-R7或-R7,
R5、R6和R7各自独立地为
(1)直链C1-22烷基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
(2)直链C2-22烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,或
(3)直链C3-22二烯基,其任选地被一个或两个选自直链C1-22烷基和直链C2-22烯基的取代基取代,
R8和R9各自独立地为C1-6烷基。
3.根据权利要求1所述的脂质纳米粒子,其中前述核酸为mRNA或DNA。
4.根据权利要求1所述的脂质纳米粒子,其中前述非阳离子脂质为磷脂、胆固醇和/或PEG脂质。
5.根据权利要求1所述的脂质纳米粒子,其中前述脂质纳米粒子在表面上具有能够靶向T细胞的配体。
6.根据权利要求5所述的脂质纳米粒子,其中前述配体是包含选自以下的一种或多种抗体的抗原结合结构域的配体:抗CD3的抗体、抗CD4的抗体、抗CD8的抗体和抗CD28的抗体。
7.根据权利要求5所述的脂质纳米粒子,其中前述配体是包含抗CD3的抗体和/或抗CD28的抗体的抗原结合结构域的配体。
8.根据权利要求5所述的脂质纳米粒子,其中前述配体是包含抗CD3的抗体和抗CD28的抗体的抗原结合结构域的配体。
9.一种药物,其包含根据权利要求1所述的脂质纳米粒子。
10.根据权利要求9所述的药物,其中所述药物是用于癌症的预防或治疗药物。
11.根据权利要求9所述的药物,其中所述药物将嵌合抗原受体或外源性T细胞受体基因引入体内免疫细胞以诱导其表达。
12.根据权利要求9所述的药物,其中所述药物将嵌合抗原受体或外源性T细胞受体基因引入体内T细胞以诱导其表达。
13.一种通过将嵌合抗原受体或外源性T细胞受体引入哺乳动物的体内免疫细胞来表达所述受体的方法,所述方法包含向所述哺乳动物施用根据权利要求1所述的脂质纳米粒子。
14.一种通过将嵌合抗原受体或外源性T细胞受体引入哺乳动物的体内T细胞来表达所述受体的方法,所述方法包含向所述哺乳动物施用根据权利要求1所述的脂质纳米粒子。
15.一种用于预防或治疗哺乳动物中的癌症的方法,所述方法包含向所述哺乳动物施用根据权利要求1所述的脂质纳米粒子。
16.根据权利要求1所述的脂质纳米粒子,其用于预防或治疗癌症。
17.根据权利要求1所述的脂质纳米粒子在制造用于预防或治疗癌症的药剂中的用途。
18.一种用于诱导嵌合抗原受体或外源性T细胞受体表达的组合物,其包含根据权利要求1所述的脂质纳米粒子。
19.一种离体免疫细胞,其表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
20.一种离体T细胞,其表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
21.一种包含离体免疫细胞的药物,所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
22.一种包含离体T细胞的药物,所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
23.根据权利要求21所述的药物,其中所述药物是用于癌症的预防或治疗药物。
24.根据权利要求21所述的药物,其中所述药物是用于诱导细胞凋亡的药物。
25.一种通过将嵌合抗原受体或外源性T细胞受体引入离体免疫细胞来表达所述受体的方法,所述方法包含将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中。
26.一种用于在离体T细胞中表达嵌合抗原受体或外源性T细胞受体的方法,所述方法包含将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中。
27.一种用于预防或治疗哺乳动物中的癌症的方法,所述方法包含向所述哺乳动物施用离体免疫细胞,所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
28.一种用于预防或治疗哺乳动物中的癌症的方法,所述方法包含向所述哺乳动物施用离体T细胞,所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
29.一种用于预防或治疗癌症的离体免疫细胞,其中所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
30.一种用于预防或治疗癌症的离体T细胞,其中所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
31.离体免疫细胞在制造用于预防或治疗癌症的药剂中的用途,其中所述离体免疫细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中获得。
32.离体T细胞在制造用于预防或治疗癌症的药剂中的用途,其中所述离体T细胞表达嵌合抗原受体或外源性T细胞受体,并且通过将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中获得。
33.一种制备药物的方法,所述药物包含表达嵌合抗原受体或外源性T细胞受体的离体免疫细胞,所述方法包含以下步骤:将根据权利要求1所述的脂质纳米粒子添加到包含离体免疫细胞的培养物中。
34.一种制备药物的方法,所述药物包含表达嵌合抗原受体或外源性T细胞受体的离体T细胞,所述方法包含以下步骤:将根据权利要求1所述的脂质纳米粒子添加到包含离体T细胞的培养物中。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017252616 | 2017-12-27 | ||
JP2017-252616 | 2017-12-27 | ||
PCT/JP2018/047872 WO2019131770A1 (ja) | 2017-12-27 | 2018-12-26 | 核酸含有脂質ナノ粒子及びその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111542338A true CN111542338A (zh) | 2020-08-14 |
Family
ID=67067602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880084376.1A Pending CN111542338A (zh) | 2017-12-27 | 2018-12-26 | 含核酸脂质纳米粒子及其用途 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210052646A1 (zh) |
EP (1) | EP3733211A4 (zh) |
JP (2) | JPWO2019131770A1 (zh) |
KR (1) | KR20200104360A (zh) |
CN (1) | CN111542338A (zh) |
AU (1) | AU2018397910A1 (zh) |
BR (1) | BR112020013201A2 (zh) |
CA (1) | CA3087147A1 (zh) |
CO (1) | CO2020008972A2 (zh) |
EA (1) | EA202091566A1 (zh) |
IL (1) | IL275567B2 (zh) |
MX (1) | MX2020006843A (zh) |
SG (1) | SG11202006033YA (zh) |
TW (1) | TW201929868A (zh) |
WO (1) | WO2019131770A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111511713A (zh) * | 2017-12-28 | 2020-08-07 | 武田药品工业株式会社 | 阳离子性脂质 |
CN114129718A (zh) * | 2021-10-19 | 2022-03-04 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
WO2024078614A1 (zh) * | 2022-10-13 | 2024-04-18 | 深圳深信生物科技有限公司 | 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3109207A1 (en) * | 2018-08-10 | 2020-02-13 | Takeda Pharmaceutical Company Limited | Cationic lipid |
WO2020080475A1 (ja) * | 2018-10-18 | 2020-04-23 | 武田薬品工業株式会社 | T細胞の活性化/増殖方法 |
CN111925448B (zh) * | 2020-08-03 | 2022-06-21 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
WO2022099003A1 (en) * | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
EP4256067A2 (en) * | 2020-12-04 | 2023-10-11 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
US11633427B2 (en) * | 2021-02-05 | 2023-04-25 | Innovative Cellular Therapeutics Holdings, Ltd. | Vaccine and uses thereof in cell therapy |
US20240050477A1 (en) * | 2021-02-17 | 2024-02-15 | National University Corporation Hokkaido University | Lipid nanoparticle |
TW202325263A (zh) | 2021-09-14 | 2023-07-01 | 美商雷納嘉德醫療管理公司 | 非環狀脂質及其使用方法 |
WO2023044333A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
TW202334080A (zh) | 2021-11-08 | 2023-09-01 | 美商歐納醫療公司 | 用於遞送環狀聚核苷酸之脂質奈米粒子組合物 |
WO2023121975A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable amine lipids and lipid nanoparticles |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
CN114939109A (zh) * | 2022-04-08 | 2022-08-26 | 华东师范大学 | 一种用于体内产生car-m的脂质纳米颗粒及其制备方法和应用 |
WO2024050551A2 (en) * | 2022-09-02 | 2024-03-07 | Oncosenx, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102119217A (zh) * | 2008-04-15 | 2011-07-06 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
US20130064894A1 (en) * | 2011-08-31 | 2013-03-14 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
US20140039032A1 (en) * | 2011-12-12 | 2014-02-06 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising cationic lipid for drug delivery system |
WO2014057432A2 (en) * | 2012-10-09 | 2014-04-17 | Universita' Degli Studi Di Roma "La Sapienza" | Multicomponent lipid nanoparticles and processes for the preparation thereof |
CN104114572A (zh) * | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
CN104159615A (zh) * | 2011-12-12 | 2014-11-19 | 协和发酵麒麟株式会社 | 含有阳离子性脂质的组合的脂质纳米粒子 |
CN104321304A (zh) * | 2012-02-24 | 2015-01-28 | 普洛体维生物治疗公司 | 三烷基阳离子脂质及其使用方法 |
CN104519915A (zh) * | 2012-06-08 | 2015-04-15 | 夏尔人类遗传性治疗公司 | 肺部递送mRNA至非肺靶细胞 |
CN105555757A (zh) * | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
WO2017019848A1 (en) * | 2015-07-28 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
CN106459989A (zh) * | 2013-12-19 | 2017-02-22 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
CN106573877A (zh) * | 2014-08-07 | 2017-04-19 | 武田药品工业株式会社 | 阳离子脂质 |
WO2017070618A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Cancer vaccines |
WO2017099823A1 (en) * | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
CN107109421A (zh) * | 2014-10-09 | 2017-08-29 | 国立大学法人山口大学 | Car表达载体及car表达t细胞 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3031916B1 (en) | 2007-06-11 | 2017-06-07 | Takara Bio Inc. | Method for expression of specific gene |
EP2350043B9 (en) | 2008-10-09 | 2014-08-20 | TEKMIRA Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
EP3207944B1 (en) | 2008-11-10 | 2020-01-15 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
RU2573409C2 (ru) * | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
EP3254672A1 (en) | 2010-06-03 | 2017-12-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
WO2013051718A1 (ja) * | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
TW201726599A (zh) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | 陽離子性脂質 |
WO2014153114A1 (en) | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
CN105873902B (zh) | 2013-11-18 | 2019-03-08 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
RS63848B1 (sr) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
WO2016073629A1 (en) * | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
EP3239132B1 (en) | 2014-12-26 | 2019-03-06 | Eisai R&D Management Co., Ltd. | Cationic lipid |
EP3303598A4 (en) | 2015-05-26 | 2019-01-23 | Ramot at Tel-Aviv University Ltd. | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES |
CN105636090A (zh) | 2015-06-30 | 2016-06-01 | 宇龙计算机通信科技(深圳)有限公司 | 业务检测方法及业务检测系统、终端和基站 |
JP7030690B2 (ja) | 2015-10-28 | 2022-03-07 | アキィタス・セラピューティクス・インコーポレイテッド | 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 |
WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
-
2018
- 2018-12-26 IL IL275567A patent/IL275567B2/en unknown
- 2018-12-26 JP JP2019562110A patent/JPWO2019131770A1/ja active Pending
- 2018-12-26 BR BR112020013201-2A patent/BR112020013201A2/pt unknown
- 2018-12-26 US US16/958,387 patent/US20210052646A1/en active Pending
- 2018-12-26 MX MX2020006843A patent/MX2020006843A/es unknown
- 2018-12-26 CA CA3087147A patent/CA3087147A1/en active Pending
- 2018-12-26 SG SG11202006033YA patent/SG11202006033YA/en unknown
- 2018-12-26 WO PCT/JP2018/047872 patent/WO2019131770A1/ja unknown
- 2018-12-26 EA EA202091566A patent/EA202091566A1/ru unknown
- 2018-12-26 CN CN201880084376.1A patent/CN111542338A/zh active Pending
- 2018-12-26 KR KR1020207021584A patent/KR20200104360A/ko not_active Application Discontinuation
- 2018-12-26 EP EP18896552.9A patent/EP3733211A4/en active Pending
- 2018-12-26 TW TW107147275A patent/TW201929868A/zh unknown
- 2018-12-26 AU AU2018397910A patent/AU2018397910A1/en active Pending
-
2020
- 2020-07-22 CO CONC2020/0008972A patent/CO2020008972A2/es unknown
-
2023
- 2023-04-28 JP JP2023075172A patent/JP2023099136A/ja active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102119217A (zh) * | 2008-04-15 | 2011-07-06 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
US20130064894A1 (en) * | 2011-08-31 | 2013-03-14 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
US20140039032A1 (en) * | 2011-12-12 | 2014-02-06 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising cationic lipid for drug delivery system |
CN104159615A (zh) * | 2011-12-12 | 2014-11-19 | 协和发酵麒麟株式会社 | 含有阳离子性脂质的组合的脂质纳米粒子 |
CN104114572A (zh) * | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
CN104321304A (zh) * | 2012-02-24 | 2015-01-28 | 普洛体维生物治疗公司 | 三烷基阳离子脂质及其使用方法 |
CN104519915A (zh) * | 2012-06-08 | 2015-04-15 | 夏尔人类遗传性治疗公司 | 肺部递送mRNA至非肺靶细胞 |
WO2014057432A2 (en) * | 2012-10-09 | 2014-04-17 | Universita' Degli Studi Di Roma "La Sapienza" | Multicomponent lipid nanoparticles and processes for the preparation thereof |
CN105555757A (zh) * | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
CN106459989A (zh) * | 2013-12-19 | 2017-02-22 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
CN106573877A (zh) * | 2014-08-07 | 2017-04-19 | 武田药品工业株式会社 | 阳离子脂质 |
CN107109421A (zh) * | 2014-10-09 | 2017-08-29 | 国立大学法人山口大学 | Car表达载体及car表达t细胞 |
WO2017019848A1 (en) * | 2015-07-28 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
WO2017070618A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Cancer vaccines |
WO2017099823A1 (en) * | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
Non-Patent Citations (16)
Title |
---|
DAVID M BARRETT ET AL: "Chimeric antigen receptor (CAR) and T cell receptor (TCR) Modified T cells Enter Main Street and Wall Street", 《J IMMUNOL.》 * |
DAVID M BARRETT ET AL: "Chimeric antigen receptor (CAR) and T cell receptor (TCR) Modified T cells Enter Main Street and Wall Street", 《J IMMUNOL.》, vol. 195, no. 3, 1 August 2015 (2015-08-01), pages 755 - 761 * |
H.F. MOFFETT ET AL: "Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers", 《NATURE COMMUNICATIONS》 * |
H.F. MOFFETT ET AL: "Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers", 《NATURE COMMUNICATIONS》, vol. 8, 30 August 2017 (2017-08-30), pages 1 - 13 * |
MARGARET M. BILLINGSLEY ET AL: "Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering", 《NANO LETT.》 * |
MARGARET M. BILLINGSLEY ET AL: "Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering", 《NANO LETT.》, vol. 20, no. 3, 11 March 2020 (2020-03-11), pages 1578 - 1589, XP055730997, DOI: 10.1021/acs.nanolett.9b04246 * |
MONIEK A. DE WITTE ET AL: "Requirements for Exective Antitumor Responses of TCR T ransduced T Cells", 《THE JOURNAL OF IMMUNOLOGY》 * |
MONIEK A. DE WITTE ET AL: "Requirements for Exective Antitumor Responses of TCR T ransduced T Cells", 《THE JOURNAL OF IMMUNOLOGY》, vol. 181, no. 7, 1 October 2008 (2008-10-01), pages 5128 - 5136 * |
TYREL T. SMITH ET AL: "In situprogramming of leukaemia-specific T cells using synthetic DNA nanocarriers", 《NAT NANOTECHNOL.》 * |
TYREL T. SMITH ET AL: "In situprogramming of leukaemia-specific T cells using synthetic DNA nanocarriers", 《NAT NANOTECHNOL.》, vol. 12, no. 8, 31 August 2017 (2017-08-31), pages 813 - 820, XP055609879, DOI: 10.1038/nnano.2017.57 * |
叶柏新,等: "脂质纳米粒-mRNA递送系统及其在嵌合抗原受体T细胞治疗中的应用", 《浙江大学学报(医学版)》 * |
叶柏新,等: "脂质纳米粒-mRNA递送系统及其在嵌合抗原受体T细胞治疗中的应用", 《浙江大学学报(医学版)》, 2 August 2022 (2022-08-02), pages 185 - 191 * |
王辉,等: "TCR BV12-3重组载体构建及其抗肿瘤作用的初步研究", 《现代生物医学进展》 * |
王辉,等: "TCR BV12-3重组载体构建及其抗肿瘤作用的初步研究", 《现代生物医学进展》, vol. 14, no. 2, 31 December 2014 (2014-12-31), pages 1 * |
葛华,等: "siRNA体内递送研究进展", 《中国新药杂志》 * |
葛华,等: "siRNA体内递送研究进展", 《中国新药杂志》, vol. 19, no. 12, 31 December 2010 (2010-12-31), pages 1031 - 1035 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111511713A (zh) * | 2017-12-28 | 2020-08-07 | 武田药品工业株式会社 | 阳离子性脂质 |
CN111511713B (zh) * | 2017-12-28 | 2024-01-02 | 武田药品工业株式会社 | 阳离子性脂质 |
US11993570B2 (en) | 2017-12-28 | 2024-05-28 | Takeda Pharmaceutical Company Limited | Cationic lipids |
CN114129718A (zh) * | 2021-10-19 | 2022-03-04 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
CN114129718B (zh) * | 2021-10-19 | 2024-05-03 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
WO2024078614A1 (zh) * | 2022-10-13 | 2024-04-18 | 深圳深信生物科技有限公司 | 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒 |
Also Published As
Publication number | Publication date |
---|---|
IL275567B2 (en) | 2024-03-01 |
MX2020006843A (es) | 2020-09-03 |
CA3087147A1 (en) | 2019-07-04 |
IL275567B1 (en) | 2023-11-01 |
JPWO2019131770A1 (ja) | 2020-12-24 |
JP2023099136A (ja) | 2023-07-11 |
WO2019131770A1 (ja) | 2019-07-04 |
EA202091566A1 (ru) | 2020-09-18 |
IL275567A (en) | 2020-08-31 |
AU2018397910A2 (en) | 2020-08-06 |
CO2020008972A2 (es) | 2020-07-31 |
BR112020013201A2 (pt) | 2020-12-01 |
EP3733211A4 (en) | 2021-11-24 |
AU2018397910A1 (en) | 2020-07-16 |
SG11202006033YA (en) | 2020-07-29 |
EP3733211A1 (en) | 2020-11-04 |
TW201929868A (zh) | 2019-08-01 |
KR20200104360A (ko) | 2020-09-03 |
US20210052646A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111542338A (zh) | 含核酸脂质纳米粒子及其用途 | |
US10392446B2 (en) | Compositions and methods to modify cells for therapeutic objectives | |
WO2021169977A1 (zh) | 新型嵌合抗原受体及其用途 | |
WO2022033537A1 (zh) | 工程化免疫细胞及其用途 | |
KR20220027855A (ko) | 원형 rna 조성물 및 방법 | |
US20210381006A1 (en) | Method for activation/proliferation of t cells | |
CN114746401B (zh) | 用于核酸递送的可离子化脂质 | |
JP7420841B2 (ja) | 核酸送達のためのイオン化可能な脂質 | |
EP3352800A1 (en) | Methods and compositions for reducing metastases | |
BR112020006292A2 (pt) | car-t modificado | |
JP2024503623A (ja) | カプセル化rnaポリヌクレオチド及び使用方法 | |
US20200215114A1 (en) | Compositions and methods for producing exosome loaded therapeutics for the treatment of multiple oncological disorders | |
CA3056819A1 (en) | Methods and compositions for stimulating immune response | |
WO2020106771A1 (en) | Compositions and methods for producing exosome loaded therapeutics for the treatment of multiple oncological disorders | |
US20230390335A1 (en) | Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof | |
RU2806549C2 (ru) | Способ активации/пролиферации t-клеток | |
JP2024515880A (ja) | 免疫応答を回避する脂質ナノ粒子治療薬 | |
Rodriguez | The antitumor activity of tumor-targeted RNA replicase-based plasmid DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |